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O-GlcNAc is a post-translational modification on serine or threonine residues by β-N-
acetylglucosamine. O-GlcNAc is added and removed from serine and threonine residues by the 
O-GlcNAc processing enzymes, O-GlcNAc-transferase (OGT) and O-GlcNAcase (OGA), 
respectively. The levels of O-GlcNAc can rapidly change in response to fluctuations in the 
extracellular environment and return to a baseline level quickly after stimulus removal. This 
process termed O-GlcNAc homeostasis is critical to the regulation of many cellular functions. 
However, the relationship between O-GlcNAc homeostasis, OGT, OGA, and gene transcription 
is unknown. In this dissertation, I seek to address some of the fundamental mechanisms into the 
control of transcription by O-GlcNAcylation. First, I explored how changes in O-GlcNAc 
homeostasis affect the transcription of OGT and OGA.  We treated several human cell lines with 
Thiamet-G (TMG, an OGA inhibitor) to increase overall O-GlcNAc levels resulting in decreased 
OGT and increased OGA protein expression. OGT transcription level slightly declined, but OGA 
significantly increased with TMG treatment. Pretreating cells with protein translation inhibitor 
cycloheximide did not stabilize OGT or OGA protein in the presence of TMG; nor did TMG 
stabilize OGT and OGA transcription when cells were treated with RNA transcription inhibitor 
actinomycin D. RNA Pol II chromatin immunoprecipitation at the OGA promoter showed that 
RNA Pol II occupancy at the transcription start site was lower after prolonged TMG treatment. 
Together, these data suggest that OGA transcription was sensitive to changes in O-GlcNAc 
homeostasis and was potentially regulated by O-GlcNAc.  
Next, we investigated how O-GlcNAcylation regulates Aγ-globin transcription. 
Erythropoiesis is the process of generating erythrocytes from erythroid progenitor cells. During 
this process, numerous genes are up-regulated or down-regulated. Transcription factor GATA-1 
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is the master regulator for erythropoiesis.  However, the mechanism underling how GATA-1 
regulate gene activation or repression is not well understood. Here, we utilized different cell and 
animal models with OGA inhibitor TMG to address this question. We first studied the Aγ-globin 
gene repression at adult stage mediated by GATA-1/FOG-1/Mi2β repressor complex at the -566 
GATA site at the Aγ-globin gene promoter. We demonstrated that OGT and OGA interact with 
the Aγ-globin promoter at the -566 GATA repressor site; however, mutation of the GATA site to 
GAGA significantly reduced OGT and OGA promoter interactions in β-YAC bone marrow cells 
(BMCs). When WT β-YAC BMCs are treated with an OGA inhibitor Thiamet-G (TMG), the 
occupancy of OGT, OGA, and Mi2β at the Aγ-globin promoter was increased. In addition, OGT 
and Mi2β recruitment was increased at the Aγ-globin promoter when γ-globin becomes repressed 
in post-conception day E18 human β-YAC transgenic mouse fetal liver. Furthermore, we showed 
that Mi2β is modified with O-GlcNAc and both OGT and OGA interacts with Mi2β, GATA-1, 
and FOG-1. Taken together, our data suggested that O-GlcNAcylation is a novel mechanism of 
γ-globin gene regulation, mediated by modulating the assembly of the GATA-1/FOG-1/Mi2β 
repressor complex at the -566 GATA motif within the promoter.  
Then, we asked if O-GlcNAc regulates GATA-1 target gene transcription during 
erythropoiesis. In this study, we utilized a well-established cell model of erythropoiesis, G1E-
ER4 cells, a murine GATA-1 null erythroblast line that undergoes erythroid differentiation when 
GATA-1 activity is restored by the addition of β-estradiol (E2). Interestingly, overall O-GlcNAc 
levels dramatically decreased after GATA-1 activation in G1E-ER4 cells, with a slight increase 
in OGA and a decrease in OGT protein levels. GATA-1 interacts with OGT/OGA, and this 
interaction increased during erythropoiesis. Transcriptome analysis of G1E-ER4 cells treated 
with E2 and Thiamet-G (TMG, an OGA inhibitor) revealed that 1,173 genes changed expression 
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patterns compared to E2 treatment only, including 433 GATA-1 target genes. These data suggest 
a subset of GATA-1 target genes are regulated through O-GlcNAcylation. Next, we 
demonstrated that the occupancy of GATA-1 and OGT/OGA, and the overall O-GlcNAc level at 
Laptm5 GATA binding site decreased when OGA was inhibited by TMG during erythropoiesis. 
Our data suggests that O-GlcNAcylation plays a role in regulating a subset of GATA-1 targeted 
erythroid genes and suggest O-GlcNAcylation as a mechanism regulating GATA-1 function at 
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Chapter 1: Introduction 
1.1 Chromatin and Transcription Initiation 
Each human diploid cell contains around 2 meters of chromosomal DNA, which is 
compacted in a tiny nucleus. How is the long DNA compacted into the tiny space? It is because 
of the help of histones, which are positive-charged proteins and bind tightly to negative-charged 
DNA. This DNA-histone complex is referred to as chromatin. A nucleosome is the basic 
structural and functional unit of the chromatin. The nucleosomes fold, loop, and coil, to form the 
chromosome (1). Each nucleosome has the following structure: two copies of histone H2A, H2B, 
H3, and H4 form an octamer, which is wrapped by approximately 1.7 turns of DNA (146 base 
pairs) (2). The addition of one histone H1 and another 20 base pairs of DNA link the adjacent 
nucleosome. The N-terminus of histones project out of the nucleosome core and form histone 
tails.  Many sites on the histone tail can be targeted for post-translational modification (PTM), 
such as acetylation, phosphorylation and methylation, which are referred to as the histone code. 
However, histone PTMs have also been found in the globular domain of core histones (3).  
The modifications on histones are epigenetic changes. Epigenetics refers to functionally 
relevant changes on chromatin or RNA without involving changes in the nucleotide sequence. 
Epigenetic regulation is dynamically regulated by epigenetic writers, readers, and erasers. 
Epigenetic writers such as histone acetyltransferases (HATs) add the modification to the targets; 
epigenetic readers such as proteins containing bromodomains bind to these epigenetic marks; and 
epigenetic erasers such as histone deacetylases (HDACs) remove the epigenetic marks. The 
integration of signaling at the epigenetic level can change many cellular processes including 
gene transcription (4-6).  
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Eukaryotic transcription is an elaborate process that eukaryotic cells use genomic DNA 
as template to syntheses pre-mRNA and later form mature mRNA. Transcription includes three 
different stages: initiation, elongation, and termination. Transcription of pre-mRNA is catalyzed 
by RNA polymerase II (Pol II), which is conserved in eukaryotes and contains 12 subunits. The 
largest subunit in RNA Pol II RPB1 has a CTD (carboxyl-terminal domain) consisting of 
multiple repeats of a heptamer YSPTSPS. The second and fifth Serine of the heptamer can be 
phosphorylated during transcription elongation (7).  
Transcription initiation by Pol II requires 5 general transcription factors (GTFs), which 
are termed as TFIID (TATA binding protein [TBP]), TFIIB, TFIIF, TFIIE, and TFIIH. In the 
first initiation step, TFIID recognizes and binds to a specific DNA sequence (TATA box) in the 
promoter. Then, TFIIB binds to both Pol II and TFIID to facilitate binding of Pol II to TFIID. In 
the third step, TFIIF binds and stabilizes the complex by recruiting TFIIE and TFIIH to the 
complex. At this point, a fully assembled pre-initiation complex (PIC) forms (8,9).   
Following formation of PIC, TFIIH DNA helicase subunit unwinds the DNA template at 
the transcription start site (TSS) in an ATP-dependent manner and creates an open complex. 
Recruitment of TFIIH also results in the phosphorylation of Pol II at Serine 5 of the CTD 
heptamer repeats.  Then the first phosphodiester bond of nascent transcripts is synthesized by Pol 
II, and transcription initiation occurs. However, the Pol II pauses and stops transcribing after 
producing a short transcript. Subsequently, pTEF-b kinase is recruited and phosphorylates CTD 
heptamer repeats at Serine 2 allowing transcription elongation (8,9). 
1.2 What is O-GlcNAc 
O-linked N-acetylglucosamine (O-GlcNAc) is a post-translational modification (PTM) 
first discovered by Gerald W. Hart and Carmen-Rosa Torres in 1984 (10). O-GlcNAc is a 
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reversible modification on serine or threonine residues by β-N-acetylglucosamine. O-GlcNAc is 
present in all higher eukaryotes studied including plants. Unlike other glycosylation, O-GlcNAc 
is not elongated to more complex structures and localized to the cytoplasm, nucleus, and 
mitochondria. Since Ser/Thr residues are also modified by phosphorylation, O-GlcNAc is often 
reciprocal with phosphorylation.  
O-GlcNAc transferase (OGT) is the enzyme that adds the O-GlcNAc modification, 
whereas O-GlcNAcase (OGA) removes it (11). The removal and addition of O-GlcNAc 
termed O-GlcNAc cycling is highly dynamic. Uridine diphosphate-N-acetyl-glucosamine (UDP-
GlcNAc), the end-point of the hexosamine biosynthetic pathway (HBP), is the high-energy donor 
substrate for OGT. Since the HBP is heavily influenced by various metabolic events including 
the metabolism of glucose, amino and fatty acids, and nucleotides, O-GlcNAcylation is sensitive 
to nutrient availability (11). O-GlcNAc regulates many cellular processes, for example, cellular 
stress response, protein translation, signal transduction, and transcription. An imbalance in the 
homeostasis of O-GlcNAc does contribute to the development of diseases including cancer, 
diabetes, and Alzheimer’s (12-14). 
  Human OGT gene is localized near centromere on X-chromosome. N-terminus of OGT 
contains 11.5 tetratricopeptide repeat (TPR) domains and C-terminus contains unique catalytic 
domain and PIP3 (phosphatidylinositol 3,4,5-trisphosphate) binding domain. OGT is found in all 
tissue and highly expressed in brain. There is no known consensus site for OGT, several proteins 
target OGT to cellular substrates, for example, OIP106, p38MAPK (11); Human OGA 
(MGEA5) is mapped to chromosome 10 and localized mostly in the cytoplasm. The N-terminus 
of OGA contains unique hyaluronidase domain and C-terminus contains putative GCN5 like 
histone-acetyltransferase. OGA can be cleaved by caspase-3 upon apoptosis but still maintains 
4 
 
activity. Both OGT and OGA are conserved across species, and knockout of OGT or OGA is 
lethal in dividing cells (11).  
The transcriptional regulation of OGT and OGA is unclear. It is suggested that the 
substantial length of introns can affect gene transcription in Drosophila (15), hence the 
transcription of OGT may also be affected since it has one or more long introns. Another study 
also proposed that PRC2 (Polycomb Repressor Complex 2) is required for maintaining normal 
Ogt protein and O-GlcNAc levels (16). However, the mechanism underlying how OGT and 
OGA are transcriptionally regulated is unknown.  
1.3 O-GlcNAcylation Regulates Transcription 
In 1989, Kelly and Hart reported that Drosophila polytene chromosomes are enriched 
with O-GlcNAc, with condensed chromatin brightly stained and transcriptionally active "puff" 
regions less stained with FITC-WGA (a lectin binds to O-GlcNAc). Furthermore, they found that 
O-GlcNAc moieties are presented on many chromatin proteins associated with other nuclear 
components (17). Later, Sakabe, et al. demonstrated that histones are modified by O-GlcNAc 
(18), and some of the O-GlcNAc sites of H2A, H2B, and H4 were identified by mass 
spectrometry (18,19). The O-GlcNAc levels of histones increase during heat shock (18) and H3 
O-GlcNAc level decreases during mitosis (20), suggesting that histone O-GlcNAc level changes 
in response to different cellular condition. O-GlcNAcylation of H2B at S112 recruits H2B 
ubiquitin ligase (BRE1A/1B) to promote H2B K120 monoubiquitination, which is a histone 
marker of transcription activation (21).  
RNA Pol II CTD is modified by O-GlcNAc at Thr 4 and Ser 5 (22), and O-GlcNAc and 
O-Phosphate of CTD are mutually exclusive (23). OGT interacts with Pol II and GTFs, such as 
TFIIA, TFIID, and TFIIF. The O-GlcNAc cycling on the CTD at gene promoter is important for 
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gene transcription (24).  In this cycle, unphosphorylated RNA Pol II (Pol IIA) CTD is first 
modified with O-GlcNAc (Pol IIγ) by OGT, promoting the association of the general 
transcription factors with Pol IIγ.  Next, O-GlcNAc is removed from Pol IIγ by OGA converting 
Pol IIγ back to Pol IIA.  Subsequently, Pol IIA is phosphorylated (Pol IIO) by TFIIH and p-
TEFb and transcription elongation occurs (24).   
OGT interacts with numerous transcription factors and mediates gene activation and 
silencing (11,19,25,26).  For example, OGT interacts with mSin3A recruiting OGT to promoters 
to repress transcription (27). Furthermore, inactivation of transcription factors and RNA 
polymerase II by O-GlcNAc modifications contribute to gene repression (27); Drosophila 
polycomb group (PcG) gene (sxc) encodes for OGT, and null mutations in OGT lead to 
polycomb defects suggesting OGT is critical for PcG medicated gene silencing (28);  Tet2 
interacts with OGT and recruits OGT to O-GlcNAcylated H2B S112 during gene transcription 
(29). In summary, O-GlcNAc can regulate gene transcription not only by modulating RNA Pol II 
and histones, but also by modifying transcription regulators such as co-activators or repressors 
through various mechanisms.  
1.4 Transcription Regulation of Erythropoiesis 
Erythropoiesis is the process in which erythroid progenitors proliferate and differentiate 
into reticulocytes. This process is regulated by numerous transcription factors. At adult stage, 
erythropoiesis is characterized by fetal γ-globin repression and activation of master transcription 
factor GATA-1. 
There are several mechanisms of fetal γ-globin silencing at adult stage. One of the well-
known γ-globin silencers is B-cell lymphoma-leukemia A (BCL11A), which forms a protein 
complex with nucleosome remodeling and deacetylase complex (NuRD), GATA-1 and SOX6 to 
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repress γ-globin expression (30). Another one is Krüppel-like factor 1 (KLF1), required for γ-
globin gene activation, which also stimulates BCL11A expression to represses γ-globin 
expression (30-32). Both BCL11A and KLF1 are positively regulated by binding of Mi2β 
(CHD4, Chromodomain Helicase DNA Binding Protein 4) a component of the NuRD complex 
(33).  We previously demonstrated that Aγ-globin gene is silenced during development following 
sequential binding of GATA-1, FOG-1 (Friend of GATA-1), and Mi2β proteins at the -566 
GATA site relative to the Aγ-globin gene CAP site in the fetal liver, between embryonic day 
E16-18 (34,35).  GATA-1 is the DNA binding moiety in this complex, but GATA-1 can recruit 
both co-activators and co-repressors in both FOG-1-dependent and independent pathways (36-
39). However, the determinants of repressor versus activator complex assembly during 
development are not well understood.  
Another characteristic of erythroid differentiation is the activation of master transcription 
factor GATA-1, resulting in up- or down-regulation of its target gene transcription. What are the 
mechanisms underlying how GATA-1 mediates gene transcription activation versus repression? 
In some instances, co-localization of GATA-1 with Scl/TAL1 at chromatin sites assures the 
recruitment of activator or repressor (40-42); to a limited degree the WGATAR adjacent motifs 
(40,43,44) and histone modifications (45,46) also play a role. However, these mechanisms do not 
take account of the protein PTMs, which can affect protein-protein interaction and chromatin 
structure.   
In this dissertation, we postulate that O-GlcNAcylation plays a role in modulating 
GATA-1/FOG-1/Mi2β repressor complex activity and regulating target gene transcription upon 
activating of GATA-1. 
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Chapter 2: O-GlcNAcase Expression is Critical in Maintaining O-GlcNAc Cellular 
Homeostasis 
“This research was originally published in Frontiers in Endocrinology. Zhen Zhang, Ee 
Phie Tan, Nicole J. VandenHull, Kenneth R. Peterson, and Chad Slawson. O-GlcNAcase 
expression is sensitive to changes in O-GlcNAc homeostasis. Front. Endocrinol. 2014, 5:206. 
doi: 10.3389/fendo.2014.00206. © 2014 Zhang, Tan, VandenHull, Peterson and Slawson.” 
O-linked N-acetylglucosamine (O-GlcNAc) is a post-translational modification (PTM) 
first discovered by Gerald W. Hart and Carmen-Rosa Torres in 1984 (10). They initially used 
bovine milk galactosyltransferase (GalT1) to probe for terminal N-acetylglucosamine 
glycoconjugates on T-cells and unexpectedly discovered the existence of single β-N-
acetylglucosamine conjugated proteins inside the cell (10). O-GlcNAc is a reversible 
modification that is ubiquitiously expressed in higher eukaryotes. O-GlcNAc transferase (OGT) 
is the enzyme that adds the O-GlcNAc modification, whereas O-GlcNAcase (OGA) removes it 
(47,48). Because uridine diphosphate-N-acetyl-glucosamine (UDP-GlcNAc), the end point of the 
hexosamine biosynthetic pathway, is the high-energy donor substrate for OGT, O-
GlcNAcylation is sensitive to nutrient availability (11). Furthermore, the removal and addition 
of O-GlcNAc termed O-GlcNAc cycling is highly dynamic. Changes in hormones, nutrients, or 
the environment cause within minutes to several hours changes to the total level of O-GlcNAc on 
proteins (49-51). Importantly, O-GlcNAc cycling rates affect transcription regulatory pathways, 
cell cycle progression, and respiration (17,24,52-54). 
Since O-GlcNAcylation plays a significant role in regulating a wide panel of cellular 
processes, and aberrant O-GlcNAcylation contributes to the development of diseases, 
understanding the regulation of OGT and OGA is, therefore, important. Several studies report 
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that the expression of OGT and OGA is sensitive to changes in total cellular O-GlcNAc levels 
(55,56). Elevation of O-GlcNAc levels via pharmacological inhibition of OGA causes OGT 
protein expression to decrease and OGA protein expression to increase (55). A rapid decrease in 
OGA protein expression occurs in mice embryonic fibroblasts when OGT is knocked out (56). 
Cells appear to actively keep a specific level of O-GlcNAcylation suggesting a certain 
homeostatic level of O-GlcNAc must be maintained for optimal cellular function. Although 
alterations of cellular O-GlcNAc levels affect OGT and OGA expression, the exact mechanism 
as to explain this phenomenon is still unclear. An imbalance in the homeostasis of O-GlcNAc 
does contribute to the development of diseases including cancer, diabetes, and Alzheimer’s (12-
14,57). 
To further address how cells adjust OGT and OGA protein expression in response to 
alterations in O-GlcNAc levels, we measured in different cell lines OGT and OGA protein and 
mRNA expression and stability after pharmacologically inhibition of OGA by Thiamet-G (TMG, 
an OGA inhibitor). In these experiments, we were able to show that the OGA mRNA levels were 
more sensitive compared to OGT to alterations in O-GlcNAc, and RNA Pol II occupancy at the 
OGA transcription start site (TSS) was decreased after prolonged TMG treatments. Altogether, 
our data show that the protein expression of OGT and OGA is sensitive to changes in O-GlcNAc 
levels, and OGA transcription is sensitive to alterations in O-GlcNAc homeostasis. 
2.1 Material and Methods 
Antibodies and Reagents 
All primary and secondary antibodies used for immunoblotting were used at a 1:1,000 
and 1:10,000 dilution, respectively. Anti-O-linked N-acetylglucosamine antibody [RL2] 
(ab2739) was purchased from Abcam. Antibodies for OGT (AL-34) and OGA (345) were 
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gracious gifts from the Laboratory of Gerald Hart in the Department of Biological Chemistry at 
the Johns Hopkins University School of Medicine. Actin (A2066) antibody and anti-chicken IgY 
HRP (A9046) were purchased from Sigma. Chromatin immunoprecipitation (ChIP) grade mouse 
(G3A1) mAb IgG1 isotype control (5415) and RNA polymerase II antibody, clone CTD4H8 (05-
623) were purchased from Cell Signaling Technologies and Millipore, respectively. Anti-rabbit 
HRP (170-6515) and anti-mouse HRP (170-6516) were purchased from Bio-Rad. 
All reagents were purchased form Sigma unless otherwise noted. Cycloheximide (CHX, 
C7698, Sigma) was used at 50 µg/ml for HeLa cells and 25 µg/ml for K562 cells (58,59). 
Actinomycin D (AMD, A1410, Sigma) was used at 0.5 µg/ml for HeLa cells and 5 µg/ml for 
K562 cells (59,60). 
Cell Culture 
HeLa cells and SH-SY5Y neuroblastoma cells were cultured in DMEM (Invitrogen) 
supplemented with 10% fetal bovine serum (FBS, Gemini) and 1% penicillin/streptomycin 
(Invitrogen). K562 cells were cultured in RPMI-1640 (Invitrogen) supplemented with 10% fetal 
bovine serum, 1× MEM non-essential amino acids solution (Invitrogen), 1 mM sodium pyruvate 
(Invitrogen), 2.5 mM HEPES, and 1% penicillin/streptomycin. Cells were treated with 10 µM 
Thiamet-G (TMG, S.D. Specialty Chemicals) for 6, 8, 24, or 48 h with fresh TMG supplied 
daily. Cells were also pretreated with CHX for 4 h, followed by TMG treatment for 8 h or AMD 
for 0.5 h, followed by TMG treatment for 6 h. Cells were infected with OGT, OGA, or green 
fluorescent protein (GFP) virus at a multiplicity of infection (MOI) of 75 for 24 h. After different 




Cells were lysed on ice for 30 min in Non-idet P-40 (NP-40) Lysis Buffer (20 mM Tris-
HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM DTT, 40 mM GlcNAc, and 1% Nonidet P-40) 
with 1 mM PMSF, 1 mM sodium fluoride, 1 mM β-glycerol phosphate, and 1× protease inhibitor 
cocktail I (leupeptin 1 mg/ml, antipain 1 mg/ml, benzamidine 10 mg/ml, and 0.1% aprotinin). 
Cell lysates were mixed with 4× protein solubility mixture (100 mM Tris-HCl, pH 6.8, 10 mM 
EDTA, 8% SDS, 50% sucrose, 5% β-mercaptoethanol, 0.08% Pyronin-Y). All electrophoresis 
was performed with 4–15% gradient polyacrylamide gels (Criterion Gels, Bio-Rad) and 
separated at 120 V, followed by transfer to PVDF membrane (Immobilon, Millipore) at 0.4 A. 
Blots were blocked by 3% BSA in TBST (25 mM Tris-HCl, pH 7.6, 150 mM NaCl, 0.05% 
Tween-20) at room temperature for 20 min, then incubated with primary antibody at 4°C 
overnight. After washing with TBST for 5 × 5 min, blots were incubated with HRP-conjugated 
secondary for 1 h at room temperature, then washed with TBST again and developed using 
chemiluminescent substrate (HyGlo E2400; Denville Scientific). Blots were stripped in 200 mM 
glycine, pH 2.5 at room temperature for 1 h and probed with different primary antibodies. All 
immunoblotting results were repeated in three independent experiments (53). OGA and OGT 
relative protein levels were measured by analyzing the bands density using ImageJ 1.48 
(http://imagej.nih.gov/ij/download.html) then normalized to the density of actin. All experiments 
were repeated three times, and average relative fold changes were calculated. 
Total RNA Isolation and RT-PCR 
Total RNA was isolated by TRI reagent solution (AM9738, Ambion) according to 
manufacture’s instruction. Briefly, 2 × 106 cells were resuspended by 1 mL TRI reagent solution. 
Then, 200 µl of chloroform was added to extract RNA. After spinning down, upper phase 
containing total RNA was collected and incubated with equal amount isopropanol. RNA pellets 
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were then precipitated by centrifugation, washed once with 70% ethanol, air-dried, and dissolved 
in nuclease free water (Invitrogen). 
RNA concentration was measured by Nanodrop 2000c (Thermo) and 1 µg of total RNA 
was used for reverse transcription (RT) using iScript Reverse Transcription Supermix (170-8841, 
Bio-Rad) following manufacturer’s instruction. In all, 10 µl of each completed reaction mix was 
incubated in a thermal cycler (Model 2720, Applied Biosystems) using the following protocol: 
priming 5 min at 25°C, RT 30 min at 42°C, and RT inactivation 5 min at 85°C. cDNA products 
were diluted with 90 µl nuclease free water and analyzed by qPCR. All qPCR results were 
repeated in three independent experiments (34). 
ChIP Assay 
K562 cells were harvested by centrifugation at 1,000 g for 5 min and washed twice with 
1× PBS. Cells were then crosslinked by 2 mM EGS (21565, Pierce) in PBS at room temperature 
for 30 min, followed by 1% formaldehyde (BP531-25, Fisher) for another 10 min. Crosslinking 
reaction was terminated by 125 mM glycine. Cell pellets were collected and lysed on ice for 30 
min by cell lysis buffer (10 mM Tris-HCl, pH 8.1, 10 mM NaCl, 0.5% NP-40) with protease 
inhibitors. Chromatin was collected by spinning down, and the pellets were resuspended in cold 
nuclear lysis buffer (50 mM Tris-HCl, pH 8.1, 10 mM EDTA, 1% SDS, 25% glycerol) with 
protease inhibitors. In total, 300 µl of nuclear lysis buffer was used to resuspend chromatin from 
2 × 106 cells.  
Chromatin DNA was sheared to the size of 100-300 bp by sonication (Model Q800R, 
Active Motif) with the following protocol: amplification 75%, pulse on 15 s, pulse off 45 s, 
temperature 3°C. 200 µl of sheared chromatin was diluted by adding 1 ml of ChIP buffer (20 
mM Tris-HCl pH8.1, 1.2% Triton X-100, 1.2 mM EDTA, 20 mM NaCl) with protease 
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inhibitors. 2 µg of control IgG and specific antibody were added to diluted chromatin 
respectively, followed by end to end rotation at 4°C overnight. At the same time, 12 µl of diluted 
chromatin was saved as input and processed later. Next day, 30 µl of PBS washed M-280 Sheep 
Anti-Mouse IgG Dynabeads (11204D, Invitrogen) was added to the chromatin, followed by 
rotating at 4°C for 4 h. Dynabeads were separated by DynaMag-2 Magnet (12321D, Invitrogen) 
and subsequently washed with 1 ml of the following buffer for 5 min at 4°C: wash buffer 1 
(0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8.0, 150 mM NaCl), wash 
buffer 2 (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8.0, 300 mM NaCl), 
wash buffer 3 (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl pH 8.0, 500 mM 
NaCl), wash buffer 4 (0.25 M LiCl, 1% NP-40, 1% sodium deoxycholate, 1 mM EDTA, 10 mM 
Tris-HCl pH 8.0), and TE buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA). 
Complexes were eluted from beads with 500 µl elution buffer (1% SDS, 0.1 M NaHCO3, 
40 mM Tris-HCl, pH 8.0, 10 mM EDTA) and added with 200 mM NaCl. Eluates and inputs 
were treated at the same time with RNase A (EN0531, Thermo) at 65°C overnight, followed by 
proteinase K (25530-031, Invitrogen) treatment for 2 h. DNA was extracted by 
phenol/chloroform/isoamyl alcohol (AC327111000, Fisher) and precipitated by glycogen 
(10814-010, Invitrogen) and ethanol (61). DNA pellets were air-dried, dissolved in 50 µl 
nuclease free water, and analyzed by qPCR. 
qPCR Assay 
cDNA or ChIP DNA samples were analyzed by qPCR using SsoAdvanced Universal 
SYBR Green Supermix (172-5271, Bio-Rad) according to manufacturer’s instruction. Briefly, 2 
µl of cDNA or 5 µl of ChIP DNA samples, SYBR green supermix, nuclease free water, and 
primers for the target gene were mixed with a total reaction volume of 20 µl. The primer 
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sequences are listed as following: OGT Fwd CATCGAGAATATCAGGCAGGAG, OGT Rev 
CCTTCGACACTGGAAGTGTATAG; OGA Fwd TTCACTGAAGGCTAATGGCTCCCG, 
OGA Rev ATGTCACAGGCTCCGACCAAGT; HPRT Fwd 
ATTGGTGGAGATGATCTCTCAACTTT, HPRT Rev 
GCCAGTGTCAATTATATCTTCCACAA; −1000 OGA TSS Fwd 
TTGGGTCTCCTTGCTGTATG, −1000 OGA TSS Rev ACCTCACAGGTTGAGATAGATTT; 
OGA TSS Fwd GGGCTAGCCTATTAAGCTTCTTTA, OGA TSS Rev 
AGGGTGGCAAGCAGAAAT; +2700 OGA TSS Fwd TCCTTTCAGAGTTGCTCCAATA, 
+2700 OGA TSS Rev CAGTCAACCGAAACCATGAAC. A 96-well PCR plate (AVRT-LP, 
Midsci) with the mixture was loaded to CFX96 Touch Real-Time PCR Detection System (185-
5195, Bio-Rad) with the following protocol: polymerase activation and DNA denaturation 30 s at 
95°C, amplification denaturation 5 s at 95°C and annealing 30 s at 60 or 62°C with 40 cycles, 
and melt curve 65–95°C with 0.5°C increment 5 s/step. 
Data Analysis 
Quantification cycle (Cq) value was recorded by CFX Manager™ software. For cDNA 
qPCR data, dynamic range of RT and amplification efficiency was evaluated before using ΔΔCq 
method to calculate relative gene expression change. For ChIP DNA qPCR data, Cq value was 
normalized to percentage of input. Data generated in three independent experiments was 
presented as means ± standard error and analyzed using two-tailed Student’s t-test with P < 0.05 
as significant difference. 
2.2 Results 
Alteration in O-GlcNAc Levels Changes the Protein Expression of OGT and OGA 
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Previous reports demonstrated that different pharmacological inhibitors of OGA, 
PUGNAc and GlcNAc-thiazoline, rapidly increase the protein expression of OGA (55,62). We 
explored this phenomenon using another highly selective inhibitor of OGA Thiamet-G (TMG) 
(63). We altered the O-GlcNAc levels of SH-SY5Y neuroblastoma, HeLa cervical carcinoma, 
and K562 leukemia cells with TMG and measured O-GlcNAc, OGT, and OGA levels at various 
time points up to 48 h of TMG treatment. The O-GlcNAc levels were increased in the TMG 
treated samples while the pattern of O-GlcNAcylation was unique to each of the three cells lines 
used. OGA protein expression increased while OGT protein expression decreased gradually in 
the prolonged TMG treatment time points (Figures 1a-c). Additionally, in SY5Y cells, we used 
adenoviral-mediated OGT or OGA infection to alter O-GlcNAc levels. GFP was used as a 
control for the adenoviral infection. Cells overexpressing OGT showed an elevation in O-
GlcNAc levels and a slight increase in OGA protein expression compared to control, while cells 
overexpressing OGA showed a decrease in O-GlcNAc levels and a slight increase in OGT 
protein expression compared to control (Figure 1d). 
TMG Does Not Stabilize OGA Protein Expression 
In order to explore the reason why TMG increases OGA protein level, we asked the 
question does TMG increase OGA protein stability. We pretreated cells with CHX to inhibit 
protein translation (64). We treated HeLa (Figure 2a) and K562 (Figure 2b) cells with TMG 
and observed a robust increase in OGA protein level (Figures 2a and b, Lane 2) compared to 
control cells without any treatment (Figures 2a and b , Lane 1). When HeLa cells were treated 
with CHX, OGT protein levels dramatically decreased compared to control, and we did not 
observe much of a decrease in OGA protein expression (Figure 2a, Lane 3). However, both 
OGT and OGA protein levels were dramatically decreased after CHX treatment in K562 cells 
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(Figure 2b, Lane 3) compared to control. Combination of CHX and TMG did not change the 
OGA or OGT protein levels (Figures 2a and b, Lane 4) compared to CHX treatment only 
suggesting that the TMG mediated increase in OGA protein expression was not due to increased 
stability of the protein. 
OGA Transcript Level is Increased after TMG Treatment 
Next, we investigated if OGT or OGA transcript level was altered after TMG treatment. 
We analyzed OGA mRNA level in SH-SY5Y (Figure 3a), HeLa (Figure 3b), and K562 
(Figure 3c) cells. We found OGA mRNA level increased from 6 h TMG treatment in all three 
cell lines and was still elevated above control after 48 h TMG treatment (Figures 3a and c). The 
OGA mRNA level corresponded with the increase in protein level in Figure 1. However, the 
OGT mRNA level did not significantly change (Figures 3d-f). We also demonstrated that the 
corresponding OGA and OGT mRNA levels increased slightly but not significantly when OGT 
or OGA were overexpressed in SH-SY5Y cells (Figures 3g and h). 
TMG Does Not Stabilize OGA mRNA 
Next, we asked the question whether increased OGA mRNA level after TMG treatment 
was due to stabilized OGA mRNA. AMD, a RNA synthesis inhibitor, was used to test OGA 
mRNA stability. TMG treated HeLa cells showed an increase of OGA mRNA level compared to 
control cells without any treatment (Figure 4a). When cells were treated with AMD, both OGA 
and OGT mRNA levels were dramatically decreased compared to control (Figures 4a and b). 
Combination of AMD and TMG did not change the OGA and OGT mRNA levels compared to 
AMD treatment only (Figures 4a and b). The same results were observed when using K562 
cells (Figures 4c and d). 
RNA Pol II Occupancy is Decreased at OGA TSS after 48 h TMG Treatment 
16 
 
We next investigated RNA Pol II occupancy at the OGA TSS via RNA Pol II ChIP. In 
control K562 cells, RNA Pol II was bound to OGA TSS with little binding upstream (−1000) or 
downstream (+2700) of the TSS. However, after 48 h TMG treatment, RNA Pol II occupancy 
was decreased at the OGA TSS compared to control cells (Figure 5a). Normal mouse IgG ChIP 
was used as a negative control (Figure 5b). 
2.3 Discussion 
The production of UDP-GlcNAc, the substrate for OGT, integrates various metabolic 
substrates allowing the O-GlcNAc modification to act as a nutrient sensor (11,65). Consequently, 
cells are sensitive to changes in O-GlcNAc levels due to nutritional and metabolic flux and will 
adjust cellular functions accordingly. Prolonged alterations in homeostatic levels of O-GlcNAc 
will cause the protein expression of OGT and OGA to change in an effort to restore O-GlcNAc 
homeostasis (11). Exactly how cells sense alterations to homeostatic levels of O-GlcNAc and 
adjust OGT and OGA expression to compensate for the changes in O-GlcNAcylation is unclear. 
For example, pharmacological inhibition of OGA rapidly increases cellular O-GlcNAc levels; 
however, the protein expression of OGA will also increase in response to the elevation of O-
GlcNAc (55,62). We sought to explore the mechanism as to how OGT and OGA protein 
expression changes in response to alterations in cellular O-GlcNAc levels. In agreement with 
previous reports, we found an increase in OGA protein expression as quickly as 8 h in HeLa cells 
and 24 h in K562 and SY5Y cells after treatment with TMG. OGT protein expression also 
decreased in these later time points (Figure 1). Due to the fact that increased levels of O-
GlcNAc can increase the stability of proteins, such as p53 (66) and TET (ten-eleven 
translocation) (67), we postulated that increased O-GlcNAc could stabilize OGA. K562 or HeLa 
cells exposed to CHX in the presence of TMG showed no difference in the stability of either 
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OGT or OGA (Figure 2) suggesting that the increase in OGA protein expression was not due to 
increased stability and more likely to an increase of OGA transcripts. 
Importantly, decreased O-GlcNAc levels do not necessarily increase OGT levels in all 
cell types; for example, blocking GFAT (glutamine fructose-6-phosphate amidotransferase) 
activity with 6-diazo-5-oxo-l-norleucine (DON) in HeLa cells lowered O-GlcNAc levels but did 
not increase OGT protein expression (55). On the other hand, OGA protein levels quickly 
decreased after Cre-mediated knockout of OGT in mouse embryonic fibroblasts (56), but OGA 
knockdown in colon cancer cells did not significantly decrease OGT protein expression (68). 
Changes in OGA protein expression appear more sensitive to changes in O-GlcNAc than OGT in 
HeLa cells, while both OGT and OGA expression significantly changed in SY5Y cells 
(Figure 1). Overexpression of OGA did not substantially influence OGT protein expression 
(Figure 1), and OGT overexpression did not change OGA expression (Figure 1). Recently, the 
development of a selective OGT inhibitor allowed for a dramatic reduction in cellular O-
GlcNAcylation (69), which in turn caused OGA protein expression to rapidly decrease with only 
a minimal increase in OGT protein expression (69). The dynamic change in OGA protein 
expression was seen in the development of disease as well. In red blood cells of prediabetic 
individuals, OGA expression was significantly increased (70), and OGA protein levels correlated 
with increased blood glucose in these prediabetic patients. These data suggest that higher blood 
glucose levels promote increased flux through the hexosamine biosynthetic pathway leading to 
elevated OGT activity, followed by OGA protein levels increasing to restore cellular O-GlcNAc 
homeostasis in erythrocyte precursor cells. Together, these data support the proposed hypothesis 
that if OGT acts as a nutrient sensor allowing for rapid changes in O-GlcNAcylation due to 
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alterations, the cellular concentration of UDP-GlcNAc (71), then OGA should be less sensitive 
to nutrient changes and more sensitive to changes in O-GlcNAcylation. 
In order to respond to changes in O-GlcNAc levels, cells rapidly and dramatically alter 
the expression of OGA mRNA (Figure 3). In the case of OGT, we did not detect a significant 
change in OGT mRNA levels after TMG treatment. The rapid increase in OGA mRNA levels 
after TMG treatment would argue that either OGA transcripts were more stable or transcriptional 
activity at the OGA promoter was increasing. We tested transcript stability by inhibiting RNA 
polymerase II with AMD (60). Interestingly, OGA and OGT transcript levels were not more 
stable after TMG treatment in the presence of AMD (Figure 4) suggesting that the increase in 
OGA mRNA levels with TMG was due to an increase in OGA gene transcription. 
Next, we performed ChIP at the OGA promoter with an antibody that recognized all 
forms of RNA Pol II (phosphorylated and non-phosphorylated forms). After 48 h of prolonged 
TMG treatment in K562 cells, total RNA Pol II at the promoter was decreased compared to the 
control samples (Figure 5). Potentially, an antibody directed against the actively transcribing 
phosphorylated C-terminal domain (CTD) of RNA Pol II might have demonstrated an increase in 
enrichment of the phosphorylated forms of RNA Pol II at the promoter while non-
phosphorylated forms of RNA Pol II would be less associated with the promoter. Interestingly, 
RNA Pol II is O-GlcNAcylated on the CTD at the fourth position of the CTD repeat, which is 
between the two activating phosphorylations at serine two and serine five on the CTD, which is 
needed for transcriptional elongation (22). Both O-GlcNAcylation and phosphorylation appeared 
to be mutually exclusive suggesting a cycle of O-GlcNAcylation and phosphorylation on the 
CTD repeats (23). Several groups have suggested that OGT and OGA work together to promote 
gene transcription by organizing the RNA Pol II preinitiation complex (PIC) (24,72). O-
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GlcNAcylation was shown to promote the formation of the PIC in an in vitro transcription assay 
system; however, OGA activity was required for full transcriptional activation suggesting that 
OGT modified RNA Pol II, which initiated the formation of the PIC, while OGA was then 
required to remove the O-GlcNAc on the stalled RNA Pol II allowing for phosphorylation and 
transcription elongation (24). We have yet to explore RNA Pol II occupancy at the OGA 
promoter after a short TMG treatment (for example 6 h), which might yield a different result and 
needs to be studied further. The mRNA levels of OGA in K562 cells did begin to decrease at the 
48 h TMG treatment suggesting that the OGA promoter might become inactive after prolonged 
TMG treatment. Reciprocal binding of OGT and OGA at active gene promoters provides several 
interesting future questions into the nature of transcriptional regulation, and the control of both 
the OGT and OGA promoter might be regulated in this manner. 
Many transcription factors are modified by O-GlcNAc (13) and likely alteration of the O-
GlcNAcylation level of a transcription factor could mediate the change in OGA transcription. 
We used the predictive software TFSEARCH 
(http://www.cbrc.jp/research/db/TFSEARCH.html) to identify potential transcription factor-
binding sites in the first 1000 base pairs upstream of the OGA TSS (73). Among the transcription 
factor-binding sites in this sequence, GATA and MZF were the most predicted transcription 
factors. Due to the essential and ubiquitous expression of OGA (11), we anticipated that several 
housekeeping transcription factors might bind to this region, but we found only few of these. 
Interestingly, both GATA and MZF are important transcription factors regulating hematopoietic 
development (34,74). Perhaps the increased in OGA expression in prediabetic red blood cells 
(70) was partially due to changes in either of these two proteins. O-GlcNAcylation changes 
might lead to alteration of GATA or MZF occupancy at the OGA promoter. Some GATA family 
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members are modified by O-GlcNAc (16); thus, this presents an interesting avenue to explore in 
more detail. 
Together, our data demonstrate that OGA protein and mRNA expression is sensitive to 
cellular levels of O-GlcNAc. Some disease states have OGA expression uncoupled from O-
GlcNAc levels (75). In many different cancers, O-GlcNAc homeostasis appears to be disrupted 
with increased OGT protein expression and O-GlcNAc levels (76). Several pancreatic cancer cell 
lines have increased O-GlcNAc levels when compared to an immortalized control cell line; 
importantly, OGT protein expression was increased while OGA protein expression was 
decreased (75). The uncoupling of OGA expression to O-GlcNAc homeostasis could be an 
indicator of cancer progression and suggest that an increase of OGA protein expression would be 
beneficial therapeutically. Determining how O-GlcNAc regulates OGA expression and 
transcription will be crucial for understanding the biology of O-GlcNAcylation and how O-







Figure 1: OGA protein level was increased after TMG treatment. a, SH-SY5Y neuroblastoma 
cells. b, HeLa cervical cells. c, K562 leukemia cells were treated with 10 µM TMG for 
indicated time. d, SH-SY5Y cells were infected with GFP, OGT, and OGA adenovirus at 75 
MOI for 24 h. Cells were lysed, overall O-GlcNAc level, OGA and OGT protein level were 
analyzed by western blot with actin as a loading control. Average fold change for OGT and 










Figure 2:TMG does not stabilize OGA protein. a, HeLa cells and (b) K562 cells were 
treated with TMG, CHX (protein translation inhibitor), and CHX + TMG. Cells were lysed, 
overall O-GlcNAc level, OGA and OGT protein level were analyzed by western blot, with 




Figure 3:OGA mRNA level was increased after TMG treatment. After TMG treatment, 
relative OGA mRNA level in (a) SH-SY5Y, (b) HeLa, and (c) K562 cells, as well as OGT 
mRNA level in (d) SH-SY5Y, (e) HeLa, and (f) K562 cells was analyzed by qPCR. (g) OGA 
mRNA level and (h) OGT mRNA level in SH-SY5Y cells infected with GFP, OGT, and OGA 
adenovirus at 75 MOI for 24 h, respectively, were also analyzed by qPCR. Hypoxanthine- 
guanine phosphoribosyltransferase (HPRT) was served as internal control. *P < 0.05. **P < 




Figure 4:TMG does not stabilize OGA mRNA. HeLa cells (a and b) and K562 cells (c and d) 
were treated with TMG, AMD (RNA transcription inhibitor), and AMD + TMG, respectively. 
OGA (a and c) and OGT (b and d) mRNA level were analyzed by qPCR, with HPRT as internal 






















Figure 5:RNA Pol II occupancy at OGA TSS was decreased after 48 h TMG treatment in K562 
cells. (a) RNA Pol II ChIP assay was performed on control and 48 h TMG treated cells. ChIP 
DNA was analyzed by qPCR using a set of primer targeting 1000 bp upstream of OGA TSS 
(−1000), OGA TSS (0), and +700 bp downstream of OGA TSS (+2700). *P < 0.05, n = 3, 
Student’s t-test. (b) Normal mouse IgG ChIP served as a negative control.  
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Chapter 3: OGT and OGA Interact with Mi2β Protein at the Aγ-Globin Promoter 
“This research was originally published in The Journal of Biological Chemistry. Zhen 
Zhang, Flávia C. Costa, Ee Phie Tan, Nathan Bushue, Luciano DiTacchio, Catherine E. 
Costelloǁ‖, Mark E. McComb, Stephen A. Whelanǁ‖, Kenneth R. Peterson, and Chad Slawson. O-
Linked N-Acetylglucosamine (O-GlcNAc) Transferase and O-GlcNAcase Interact with Mi2β 
Protein at the Aγ-Globin Promoter. The Journal of Biological Chemistry.  2016, 291:15628-40. © 
the American Society for Biochemistry and Molecular Biology.” 
The human β-globin gene cluster is comprised of five functional β-like globin genes: an 
embryonic gene (ε), duplicated fetal γ genes (Gγ and Aγ), a minor adult gene (δ) and the adult β 
gene, which are expressed during development in the same order as they are arrayed, 5’-ε-Gγ-Aγ-
δ-β-3’. The expression of these genes is not only controlled by an upstream locus control region 
(LCR), but also regulated by epigenetic signals, as well as transcription factors and their DNA 
binding motifs (32,77-79). There are two major switches of human β-like globin gene expression 
during development. The first switch is from embryonic to fetal globin, characterized by 
silencing of the embryonic ε-globin gene in the yolk sac and activation of the fetal γ-globin 
genes in the liver. The second switch is from the fetal to adult globins, characterized by the 
progressive silencing of γ-globin gene expression in the liver, and activation of adult globins (δ 
and β) in bone marrow (30). 
Patients with sickle cell disease (SCD), caused by a point mutation in the β-globin gene, 
suffer chronic damage of multiple organs, increased risk of stroke, as well as cardiovascular 
abnormalities and dysfunction (80,81). However, SCD pathophysiology is ameliorated if the 
patients carry compensatory mutations that result in continued expression of the fetal γ-globin 
genes (fetal hemoglobin, HbF), a condition called hereditary persistence of fetal hemoglobin 
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(HPFH) (31).  Thus, a logical clinical goal for treatment of this β-hemoglobinopathy is to up-
regulate γ-globin synthesis (31).  There are several mechanisms of γ-globin silencing. One of the 
well-known γ-globin silencers is B-cell lymphoma-leukemia A (BCL11A), which forms a 
protein complex with nucleosome remodeling and deacetylase complex (NuRD), GATA-1 and 
SOX6 to repress γ-globin expression (30). Krüppel-like factor 1 (KLF1), required for γ-globin 
gene activation, also stimulates BCL11A expression, which in turn represses γ-globin expression 
(30-32).  Both BCL11A and KLF1 are positively regulated by binding of Mi2β (CHD4, 
Chromodomain Helicase DNA Binding Protein 4) a component of the NuRD complex (33).  We 
previously demonstrated another modality of fetal globin repression using human γ-globin locus 
yeast artificial chromosome (β-YAC) transgenic mice.  The Aγ-globin gene is silenced during 
development following sequential binding of GATA-1, FOG-1 (Friend of GATA-1), and Mi2β 
proteins at the -566 GATA site relative to the Aγ-globin gene CAP site in the fetal liver, between 
post-conception days E16-18 (34,35).  GATA-1 is the DNA binding moiety in this complex, but 
GATA-1 can recruit both coactivators and corepressors in both FOG-1-dependent and 
independent pathways (36-39). The determinants of repressor versus activator complex assembly 
during development are not well understood. We postulate that one potential mechanism is 
through post-translational modifications (PTM) such as O-GlcNAcylation. 
O-GlcNAcylation is the attachment of a single N-acetyl-glucosamine moiety to serine or 
threonine residues in mitochondrial, nuclear and cytoplasmic proteins.  The enzyme O-GlcNAc 
transferase (OGT) adds the modification to proteins while O-GlcNAcase (OGA) removes the 
modification (11).  O-GlcNAcylation integrates signals from a variety of nutrients in order to 
regulate cell signaling pathways, transcription, and cellular metabolism (82).   Furthermore, the 
rate of O-GlcNAc cycling (the addition and then removal of O-GlcNAc) affects cell cycle 
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progression, mitotic signaling and spindle formation, and cellular respiration 
(11,13,14,53,54,83).  Both OGT and OGA are essential for cellular function.  Knockout 
mutations of OGT or OGA are embryonic lethal (84,85). Disruption of O-GlcNAcylation 
contributes to the development of diseases including cancer, diabetes, and Alzheimer’s (12-
14,57,86). 
Growing evidence demonstrates that O-GlcNAcylation plays an important role in 
regulating transcription.  O-GlcNAcylation is part of the histone code, and histones are O-
GlcNAcylated under diverse cellular conditions (18,20,21).  A recent study suggests that O-
GlcNAc cycling also plays an important role in maintaining the epigenetic machinery in 
Drosophila (87). The RNA Pol II carboxy terminal domain (CTD) is modified by O-GlcNAc 
(22) facilitating pre-initiation complex (PIC) formation (24). Furthermore, numerous 
transcription factors are modified by O-GlcNAc and interact with OGT (11,25,27,29,88-90).  
Thus, O-GlcNAcylation could potentially regulate γ-globin gene transcription. 
In this study, we asked the question whether O-GlcNAcylation plays a role in organizing 
the Aγ-globin promoter.  Herein, we demonstrate that both OGT and OGA interact with the Aγ-
globin promoter in both immortalized β-YAC bone marrow cells (BMCs) and in β-YAC 
transgenic mouse fetal liver. The occupancy of OGT, OGA, and Mi2β at the Aγ-globin promoter 
is increased after TMG (an OGA inhibitor) treatment. Furthermore, we show that Mi2β is 
modified by O-GlcNAc and both OGT and OGA interact with GATA-1/FOG-1/Mi2β repressor 
complex.  Taken together, our data suggest that O-GlcNAcylation is a novel mechanism that 
regulates Aγ-globin gene expression by modulating GATA-1/FOG-1/Mi2β repressor complex 
recruitment to the -566 GATA site in the promoter during development. 




Primary antibodies and secondary antibodies for immunoblotting were used at a 1:1,000 
and 1:10,000 dilution respectively. Antibodies for chromatin immunoprecipitation (ChIP) assay 
were used at 2 µg per reaction. 
Antibodies for immunoblotting: O-GlcNAc (CTD 110.6), OGT (AL-34) and OGA (345) 
were gracious gifts from the Laboratory of Gerald Hart in the Department of Biological 
Chemistry at the Johns Hopkins University School of Medicine. Anti-O-linked N-
acetylglucosamine antibody [RL2] (ab2739), anti-GAPDH antibody (ab9484), and anti-CHD4 
antibody [3F2/4] (ab70469) were purchased from Abcam. Actin antibody (A2066), anti-chicken 
IgY HRP (A9046), and anti-mouse IgM HRP (A8786) were purchased from Sigma. Goat anti-
rabbit IgG HRP (170-6515) and goat anti-mouse IgG HRP (170-6516) were purchased from Bio-
Rad. Rabbit anti-goat IgG HRP (31402) was purchased from Thermo Scientific. Goat anti-rat 
IgG HRP (NA935V) was purchased from GE Healthcare.  Mi2β Antibody (H-242) (sc-11378 X, 
also used for ChIP assay), GATA-1 antibody (sc-265 X), FOG antibody (sc-9361 X), normal 
rabbit IgG (sc-2027), normal chicken IgY (sc-2718), normal mouse IgG (sc-2025) and IgM (sc-
3881), rat IgG (sc-2026), and normal goat IgG (sc-2028) were purchased from Santa Cruz 
Biotechnology.  Antibodies for chromatin immunoprecipitation (ChIP): Rabbit control IgG 
(ab46540) was purchased from Abcam. OGT antibody (61355) was purchased from Active 
Motif.  Anti-OGA antibody (SAB4200267) was purchased from Sigma. 
Cell Culture 
K562 cells were cultured in RPMI-1640 (R8758, Sigma) supplemented with 10% heat-
inactivated fetal bovine serum (FBS, 100-106, Gemini), 1X MEM non-essential amino acids 
solution (Sigma), 1 mM sodium pyruvate (Sigma), 2.5 mM HEPES (Sigma), and 1X 
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penicillin/streptomycin (Sigma).  K562 cells were treated with 10 µM Thiamet-G (TMG, S.D. 
Specialty Chemicals) for 6 hrs, followed by 0.75 mM sodium butyrate (NaB, B5887, Sigma) for 
4 days or 10 µM hemin (51280, Sigma) and 3 mM N,N'-Hexamethylenebisacetamide (HMBA, 
208320500, Acros Organics) for 3 days (34). 
Wild-type (WT) and -566 Aγ-globin mutant murine chemical inducer of dimerization 
(CID)-dependent human β-YAC BMCs were generated as previously described (34,35).  WT 
CID-dependent β-YAC BMCs have the normal GATA sequence at -566 of the Aγ-globin 
promoter, while -566 mutant CID-dependent β-YAC BMCs have a T>G point mutation at 
nucleotide -566.  Cells were cultured in HyClone Iscove’s Modified Dulbecco’s Medium 
(IMDM, SH30005.02, Thermo Scientific) supplemented with 10% heat-inactivated FBS 
(Gemini), 1X penicillin/streptomycin (Sigma) and the CID, 5 µM CL-COB-II-293 (synthesized 
by the University of Kansas COBRE CCET Core C Synthesis Lab, commonly called AP20187).   
The cells were passaged at 2 x 105 cells/ml every three days in the presence of CL-COB-II-293 
(91).  WT β-YAC BMCs were treated with 10 µM TMG for 4 days, with fresh TMG and culture 
medium supplied daily.  
Murine erythroleukemia (MEL) cell line stably expressing bacteria biotin ligase birA is a 
kindly gift from the Laboratory of Alan B. Cantor at Harvard Medical School, and cultured as 
previously described (42).  All cells were incubated at 37°C, 5% CO2 in a 95% humidified 
incubator. 
Immunoprecipitation 
Cells were lysed on ice for 30 min in Nonidet P-40 (NP-40) Lysis Buffer (20 mM Tris-
HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM DTT, 40 mM GlcNAc, and 1% NP-40) 
supplemented with 1 mM PMSF, 1 mM sodium fluoride, 1 mM β-glycerol phosphate, and 1X 
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protease inhibitor cocktail I (1 µg/ml leupeptin, 1 µg/ml antipain, 10 µg/ml benzamidine and 
0.1% aprotinin).  Two mg of cell lysates were incubated with 2 µg of antibody in a 1 ml reaction 
volume overnight with end-to-end rotation at 4°C.  Next day, 20 µl of anti-Mouse IgM (µ-chain 
specific)-Agarose (A4540, Sigma), Protein G Sepharose 4 Fast Flow (17-0618-01, GE), or anti-
Chicken IgY Agarose (DAIgY-AGA-2, Gallus Immunotech) slurry were added into the mixture, 
followed by end-to-end rotation at 4°C for 2 hrs.  Agarose beads were washed 3x with 1 ml NP-
40 Lysis Buffer and mixed with 20 µl 2X protein solubility mixture (50 mM Tris-HCl, pH 6.8, 5 
mM EDTA, 4% SDS, 25% sucrose, 2.5% β-mercaptoethanol, 0.04% Pyronin-Y).  Forty µg of 
cell lysates were mixed with 4X protein solubility mixture as input.  The beads and input were 
heated at 95°C for 2 min and were subjected to immunoblotting. 
Immunoblotting 
All electrophoresis was performed with 4-15% gradient Criterion TGX Precast Gels 
(567-1084, Bio-Rad) at 140 volts, followed by transferring protein to PVDF membrane 
(IPVH00010, Millipore) at 0.4 Amps.  Blots were blocked by 3% BSA in TBST (25 mM Tris-
HCl, pH 7.6, 150 mM NaCl, 0.05% Tween-20) at room temperature for 20 min, then incubated 
with primary antibody at 4°C overnight.  After washing with TBST 5x for 5 min each time, blots 
were incubated with HRP-conjugated secondary antibody for 1 hr at room temperature, followed 
by TBST washes again and developed using chemiluminescent substrate (E2400, Denville 
Scientific).  Blots were stripped in 200 mM glycine, pH 2.5 at room temperature for 1 hr and 
probed with other primary antibodies.  All immunoblotting results were repeated in three 




WT and -566 Aγ-globin mutant CID-dependent b-YAC BMCs were used or WT β-YAC 
transgenic mouse fetal liver single cell suspensions were prepared as previously described 
(34,35).  Briefly, fetal liver from WT β-YAC transgenic mice at 12 and 18 days post-conception 
(E12 or E18) were isolated and kept on ice in 1X PBS.  The liver tissue was cut into small pieces 
with a scissor and a single cell suspension was prepared by repeatedly passing the liver pieces 
through a 1 ml syringe with sequentially smaller needle sizes (16-, 18- and 20-gauge, BD 
Biosciences) and then subjected to ChIP assay. 
The ChIP assay was performed using a previously described method (92) with slight 
modifications.  Briefly, cells were cross-linked by 2 mM EGS (21565, Pierce) in PBS for 30 min, 
followed by 1% formaldehyde (BP531-25, Fisher) for 10 min at room temperature.  The cross-
linking reaction was terminated by the addition of 2.5 M glycine to a final concentration of 125 
mM.  Cells were lysed and chromatin was collected by centrifugation at 1,000x g.  Three 
hundred µl of Nuclear Lysis Buffer (50 mM Tris-HCl, pH 8.1, 10 mM EDTA, 1% SDS, 40 mM 
GlcNAc, and 25% glycerol) was used to resuspend chromatin pellets from 5 x 106 cells. 
Chromatin DNA was sheared to the size of 100~300 bp and immuoprecipitated with 2 µg of 
control IgG or specific antibody, respectively, at 4°C overnight.  Next day, 30 µl of PBS-washed 
M-280 Sheep Anti-Rabbit IgG Dynabeads (11204D, Invitrogen) were added to the chromatin, 
followed by rotation at 4°C for 4 hrs.  Dynabeads were separated using a DynaMag-2 Magnet 
(12321D, Invitrogen) and subsequently washed and eluted as previously described (92). The 
eluate was subjected to reverse cross-linking by sequential treatments with RNAse A and 
proteinase K (92).  ChIP DNA was extracted as previously described (92), and dissolved in 50 µl 
nuclease free water (AM9906, Ambion), followed by quantitative PCR (qPCR). 
Total RNA Isolation and RT-PCR 
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Total RNA was isolated as previously described (92). Briefly, RNA was isolated from 2 x 
106 cells using TRI reagent solution (T9424, Sigma) according to the manufacturer’s 
instructions.  For reverse transcription (RT), 0.5 µg of total RNA was used in iScript Reverse 
Transcription Supermix (170-8841, Bio-Rad) following the manufacturer’s instructions.  Ten µl 
of each completed reaction mix was incubated in a thermal cycler (Model 2720, Applied 
Biosystems) using the following protocol: priming 5 min at 25°C, RT 30 min at 42°C, and RT 
inactivation 5 min at 85°C. cDNA products were diluted with 90 µl nuclease free water and 
analyzed by qPCR.  
qPCR Assay 
cDNA and ChIP DNA were analyzed by qPCR as described previously (92) and 
according to the manufacturer’s instructions. Two µl of cDNA or 5 µl of ChIP DNA sample, 10 
µl of SsoAdvanced Universal SYBR Green Supermix (172-5271, Bio-Rad), nuclease free water, 
and primers for the target gene were mixed together in a total reaction volume of 20 µl.  The 
primer sequences are listed as following: Human γ-globin Fwd 
GTATTGCTTGCAGAATAAAGCC, Rev GACCGTTTTGGCAATCCATTTC; Mouse HPRT 
Fwd GGCCAGACTTTGTTGGATTTG, Rev CGCTCATCTTAGGCTTTGTATTTG; Aγ-globin 
Promoter Fwd CTAATCTATTACTGCGCTGA, Rev GTTTCTAAGGAAAAAGTGCT; Human 
OGT Fwd CATCGAGAATATCAGGCAGGAG, Rev CCTTCGACACTGGAAGTGTATAG; 
Human OGA Fwd TTCACTGAAGGCTAATGGCTCCCG, Rev 
ATGTCACAGGCTCCGACCAAGT; Human HPRT Fwd 
ATTGGTGGAGATGATCTCTCAACTTT, Rev GCCAGTGTCAATTATATCTTCCACAA. 
The reactions were run in a CFX96 Touch Real-Time PCR Detection System (185-5195, Bio-
Rad) using the following conditions: polymerase activation and DNA denaturation 30 s at 95°C, 
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amplification denaturation 5 s at 95°C, and amplification annealing and extension 30 s at 60°C or 
62°C for 40 cycles. 
qPCR Data Analysis 
Quantification cycle (Cq) values were calculated by CFX Manager™ software.  For 
cDNA qPCR data, the dynamic range of RT and amplification efficiency was evaluated before 
applying the ∆∆Cq method to calculate relative gene expression change.  The transcription level 
of the target gene was normalized to the internal control as fold change. For ChIP DNA qPCR 
data, the Cq value was normalized as percent of input.  Data generated in three independent 
experiments are presented as mean ± standard error; the two-tailed Student t-test statistic was 
applied with P < 0.05 considered to be a significant difference. 
3.2 Results 
OGT and OGA interact with the Aγ-globin gene promoter 
To determine whether OGT and OGA interact with the Aγ-globin gene promoter, we 
utilized WT and -566 mutant murine CID-dependent β-YAC BMCs (34,35).  At the -566 region 
of the Aγ-globin promoter relative to the CAP site, WT β-YAC BMCs have a GATA motif that is 
bound by a GATA-1/FOG-1/Mi2β repressor complex when γ-globin is silenced during the adult 
stage of hematopoiesis.  In the -566 mutant β-YAC BMCs, a T>G point mutation at nucleotide -
566 (Figure 6a) results in an HPFH phenotype.  This mutation changes the GATA site to a 
GAGA site preventing binding of the GATA-1/FOG-1/Mi2β repressor complex, and results in 
continued γ-globin gene transcription in the adult stage of erythropoiesis (Figure 6b).  Both WT 
and -566 mutant β-YAC BMCs express OGT and OGA, and have similar overall O-GlcNAc 
levels (Figure 6c).  Next, we performed ChIP assays in both of these BMC populations to test 
for OGT and OGA occupancy at the Aγ-globin promoter.  In WT β-YAC BMCs both OGT and 
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OGA associated with the -566 region of the Aγ-globin promoter; however, in -566 mutant β-
YAC BMCs, this association was dramatically decreased (Figure 6d).  These data suggest that 
OGT and OGA interact with component(s) of the GATA-1/FOG-1/Mi2β repressor complex at -
566 GATA site of Aγ-globin promoter. 
OGT, OGA and Mi2β increase at the Aγ-globin gene promoter after TMG treatment 
             Our data suggest that OGT and OGA play a role in regulating γ-globin transcription by 
modulating GATA-1/FOG-1/Mi2β repressor complex activity at the Aγ-globin promoter. To test 
this hypothesis, we treated the WT β-YAC BMCs for 4 days with Thiamet-G (TMG, S.D. 
Specialty Chemicals), a competitive inhibitor of OGA, to increase overall O-GlcNAc levels. 
After TMG treatment for 4 days, the overall O-GlcNAc levels were increased, with increased 
OGA and decreased OGT protein level (Figure 7a), a similar effects that we observed 
previously (92). Interestingly, the γ-globin transcription level was decreased (Figure 7b). In 
order to seek the mechanism of deceased γ-globin transcription after TMG treatment, we 
performed ChIP assays on WT β-YAC BMCs. After TMG treatment for 4 days, the occupancy 
of both OGT and OGA was increased at the Aγ-globin promoter compared to the cells without 
TMG treatment (Figure 7c). We also observed an increase of Mi2β occupancy at Aγ-globin 
promoter after TMG treatment (Figure 7d). These data demonstrate that OGT, OGA, and Mi2β 
increase at the Aγ-globin promoter after TMG treatment.  
OGT and OGA interact with the Aγ-globin promoter during fetal liver development 
In β-YAC transgenic mice, the γ-globin gene is expressed during early fetal development; 
however, prior to birth γ-globin expression is silenced in hematopoietic cells of the fetal liver, 
partly through the gradual recruitment of the GATA-1/FOG-1/Mi2β repressor complex (34,35).  
To determine if OGT and OGA associate with the Aγ-globin promoter during different fetal 
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stages of hematopoietic development as gene silencing progresses, we performed ChIP assays in 
β-YAC transgenic mouse fetal liver single cell suspensions to test for recruitment of Mi2β, OGT 
and OGA.  At post-conception day 12 (E12), γ-globin is expressed in the murine fetal liver.  
However, γ-globin is repressed at post-conception day 18 (E18), when the GATA-1/FOG-
1/Mi2β repressor complex is recruited to the -566 Aγ-globin GATA silencer site (34).  As a 
positive control for repressor complex binding, we confirmed our previous data (34) that Mi2β 
binds to the Aγ-globin promoter at day E18 when γ-globin is repressed, but not in day E12 fetal 
liver when γ-globin is expressed (Figure 8a).  Interestingly, OGT occupancy was slightly 
increased at the Aγ-globin promoter at day E18 compared to day E12 (Figure 8b).  We did not 
observe an increase of OGA occupancy at the Aγ-globin promoter at day E18 compared to day 
E12, although OGA interacts with the promoter on both days (Figure 8c).  These data suggest 
that recruitment of OGT and OGA to the Aγ-globin promoter may contribute to Aγ-globin gene 
silencing. 
Mi2β is modified by O-GlcNAc 
Since OGT and OGA interact with the Aγ-globin promoter where the GATA-1/FOG-
1/Mi2β repressor complex binds, we determined whether any component(s) of the repressor 
complex is modified by O-GlcNAc.  For these experiments, we used human erythroleukemia 
K562 cells, a well-established model system for globin studies (93).  The addition of sodium 
butyrate (NaB) to K562 cells increases γ-globin expression (93).  Our experiments confirmed 
this phenotype; the γ-globin mRNA level was increased by NaB as expected (Figure 9a).  After 
4 days treatment, overall O-GlcNAc levels were decreased, with an increase of OGA protein 
level and a decrease of OGT protein level (Figure 9b), which corresponded to an increased OGA 
mRNA level (Figure 9c) and a decreased OGT mRNA level (Figure 9d).  We also used hemin 
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and HMBA (H-H), another well-established inducer of differentiation in K562 cells (34) that 
also relieves γ-globin repression (data not shown).  We used these two different methods to 
alleviate Aγ-globin promoter repression in order to eliminate any artifacts from these chemical 
inducers that could skew the data. 
Next, we assessed if any proteins of the GATA-1/FOG-1/Mi2β complex were modified 
by O-GlcNAc pre- or post-γ-globin promoter activation.  We used a specific antibody to O-
GlcNAc to immunoprecipitate potential O-GlcNAc modified proteins from K562 lysates before 
and after NaB treatment. TMG was used to increase the overall O-GlcNAc levels by 
competitively inhibiting OGA. Blots were probed individually with Mi2β, FOG-1, and GATA-1 
antibodies, respectively.  We found that CTD 110.6 immunoprecipitated Mi2β before NaB 
treatment (Day 0), and TMG treatment increased the amount of Mi2β immunoprecipitated by 
CTD 110.6. However, CTD 110.6 immunoprecipitated Mi2β protein level was decreased after 4 
days of NaB treatment (Figure 10a, top panel).  Similar results were observed when using H-H 
as inducer instead of NaB (Figure 10a, bottom panel). 
We also performed the converse immunoprecipitation using Mi2β antibody and probed 
the blot for O-GlcNAc.  Mi2β was O-GlcNAc modified prior to NaB induction, and this 
modification dramatically decreased after 4 days of NaB treatment (Figure 10b, top panel).  The 
same results were obtained when H-H were used as inducer (Figure 10b, bottom panel). These 
data suggest that O-GlcNAcylation of Mi2β changes during γ-globin induction. 
We also performed two control experiments to further validate O-GlcNAcylation of 
Mi2β.  Mi2β was immunoprecipitated from duplicate sets of lysates. Both sets were transferred 
to a PVDF membrane, which was cut in half.  One set was probed with CTD 110.6 antibody 
detecting O-GlcNAcylated Mi2β (Figure 10c).  However, detection of O-GlcNAcylated Mi2β 
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on the other set was abolished when CTD 110.6 antibody was pre-incubated with 500 mM free 
GlcNAc (Figure 10d).  In another experiment, Mi2β immunoprecipitates were treated with 
CpNagJ hexosaminidase (gift from Daan van Aaltan, University of Dundee), which removes 
oxygen-linked hexoses from proteins (94).  In the absence of CpNagJ treatment, Mi2β 
immunoprecipitates were O-GlcNAcylated, while detection of the Mi2β O-GlcNAcylation was 
completely lost after CpNagJ treatment (Figure 10e). 
Mi2β interacts with OGT 
Since Mi2β is modified by O-GlcNAc, we next explored if Mi2β interacts with OGT.  
First, we performed IP experiments using OGT antibody on lysates prepared from K562 cells 
that had been treated with or without NaB.  OGT interacts with Mi2β prior to NaB induction but 
not after 4 days of NaB induction (Figure 11a). The lost interaction of OGT and Mi2β after NaB 
treatment corresponds to the decreased O-GlcNAcylation of Mi2β after NaB induction (Figure 
11a and b, top panel).  Similar IP results were observed when cells were differentiated by H-H 
for three days (Figure 11b). 
We also performed IPs against Mi2β in K562 cell lysates prior to and following NaB 
induction.  Mi2β antibody was able to co-IP OGT prior to NaB treatment, but unable to 
immunoprecipitate OGT after 4 days of NaB treatment (Figure 11c).  The same results were 
seen when we used H-H to differentiate cells (Figure 11d).  These data demonstrate that Mi2β 
interacts with OGT before induction of γ-globin in K562 cells or prior to their terminal 
differentiation, but not after treatments that induce HbF or terminal erythroid differentiation. 
Mi2β interacts with OGA 
Since our data demonstrated OGA also interacts at the -566 region of the Aγ-globin 
promoter, we next tested whether Mi2β interacts with OGA as well.  We performed co-IP 
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experiments as described in the previous section.  OGA antibody was able to co-IP Mi2β prior to 
and after NaB induction (Figure 12a).  Similar co-IP results were observed when cells were 
differentiated by H-H (Figure 12b).  As described above for the Mi2β-OGT interaction 
experiments, we performed the converse co-IP using Mi2β antibody and looked for interactions 
with OGA.  Mi2β antibody was able to co-IP OGA prior to and after NaB treatment (Figure 
12c).  The same results were obtained when we used H-H to differentiate cells (Figure 12d). 
These data indicate that Mi2β interacts with OGA before and after induction of γ-globin in K562 
cells. 
OGT and OGA interact with GATA-1 and FOG-1  
             Our data demonstrated that both OGT and OGA interact with Mi2β, a component of 
GATA-1/FOG-1/Mi2β repressor complex. Thus, OGT and OGA might also interact with 
GATA-1 and FOG. In order to confirm the interaction of OGT/OGA with GATA-1/FOG-1, we 
performed IPs in MEL birA cells (42) since they express relative higher GATA-1 and FOG-1 
protein compared to K562 and β-YAC BMCs (data not shown).  GATA-1 antibody was able to 
pull down both OGT and OGA (Figure 13a); FOG-1 antibody can also pull down OGT and 
Mi2β (Figure 13b); and OGA antibody was able to IP FOG-1 (Figure 13c). These data suggest 
that OGT and OGA can also interact with GATA-1 and FOG-1 besides Mi2β. 
3.3 Discussion 
Using WT and -566 mutant CID-dependent β-YAC BMCs, we demonstrated that both 
OGT and OGA interact with the Aγ-globin promoter (Figure 6) at the -566 GATA site occupied 
by the GATA-1/FOG-1/Mi2β repressor complex when γ-globin is silenced.  In addition, the 
occupancy of OGT, OGA and Mi2β at the Aγ-globin promoter is increased after TMG treatment 
(Figure 7). In β-YAC transgenic mouse fetal liver, OGT and Mi2β recruitment was increased at 
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the -566 GATA site of the Aγ-globin promoter at post-conception day E18 when γ-globin is 
repressed compared to day E12 when γ-globin is expressed (Figure 8).  Furthermore, we 
determined that Mi2β is modified by O-GlcNAc (Figure 10), and OGT/OGA interacts with 
GATA-1/FOG-1/Mi2β repressor complex (Figure 11-13). Taken together our data suggest that 
O-GlcNAcylation plays a role in regulating Aγ-globin gene expression via recruitment of the 
GATA-1/FOG-1/Mi2β repressor complex at the -566 GATA site of the Aγ-globin promoter. 
O-GlcNAcylation plays an important role in controlling transcription. O-GlcNAc 
regulates gene transcription by directly modifying transcription factors/co-factors, RNA Pol II 
CTD (24), or by altering how the activity of these factors is modulated by other PTMs (25). A 
previous study by Ranuncolo et al. suggested that an O-GlcNAcylation cycle on RNA Pol II C-
terminal domain (CTD) occurs at gene promoters.  In this cycle, unphosphorylated RNA Pol II 
(Pol IIA) CTD is first modified with O-GlcNAc (Pol IIγ) by OGT, promoting the association of 
the general transcription factors with Pol IIγ.  Next, O-GlcNAc is removed from Pol IIγ by OGA 
converting Pol IIγ back to Pol IIA.  Subsequently, Pol IIA is phosphorylated (Pol IIO) by TFIIH 
and P-TEFb and transcription elongation occurs (24).  Correspondingly, we demonstrated that 
both OGT and OGA interact with the Aγ-globin promoter in β-YAC BMCs (Figure 6d) and β-
YAC transgenic mouse fetal liver (Figure 8b and c). The addition of TMG to the β-YAC BMCs 
decreased OGA activity and reduced O-GlcNAc cycling of Mi2β at the Aγ-globin promoter 
leading to the recruitment of more OGA to the Aγ-globin promoter to maintain the normal O-
GlcNAc cycling (Figure 7c). In addition, TMG can also increase the Mi2β O-GlcNAc levels 
resulting in the extended occupancy of Mi2β (Figure 7d), other components of the GATA-
1/FOG-1/Mi2β repressor complex, and OGT (Figure 7c) at the Aγ-globin promoter. All the 
above effects caused by TMG treatment could stabilize GATA-1/FOG-1/Mi2β repressor 
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complex and reduce the γ-globin transcription level (Figure 7b). Furthermore, these data suggest 
that both OGT and OGA interactions at the Aγ-globin promoter are important for the recruitment 
and organization of the GATA-1/FOG-1/Mi2β repressor complex at the -566 GATA site. Similar 
to the assembly of the PIC at gene promoters described by Ranuncolo et al., the assembly of the 
GATA-1/FOG-1/Mi2β repressor complex at Aγ-globin promoter might also require the O-
GlcNAcylation of Mi2β first to recruit other factors, followed by OGA removal of the O-
GlcNAc. 
Although the GATA-1/FOG-1/Mi2β repressor complex is assembled sequentially during 
development in a murine model (35), the mechanisms controlling this assembly are unknown. 
Our data show that Mi2β is modified by O-GlcNAc (Figure 10). O-GlcNAcylation of Mi2β may 
facilitate the sequential recruitment of Mi2β to the GATA-1/FOG-1 proteins already bound at the 
Aγ-globin promoter. Mi2β/NuRD also mediates Aγ-globin gene silencing independent of the 
GATA-1/FOG-1/Mi2β repressor complex at the -566 GATA site of the Aγ-globin promoter. 
Mi2β binds directly to BCL11A and KLF1, and positively regulates BLC11A and KLF1 
expression, which in turn leads to γ-globin silencing (33). Thus, O-GlcNAcylation of Mi2β likely 
plays a role in mediating γ-globin silencing by affecting the action of several previously 
identified γ-globin repressor complexes that interact with different cis-regulatory motifs in the 
promoters of the γ-globin genes. 
The GATA-1/FOG-1/Mi2β repressor complex mediates one mode of Aγ-globin gene 
silencing; the components of which are sequentially recruited to the -566 GATA silencer of the 
Aγ-globin promoter (34,35).  How this repressor complex is assembled and organized during 
development is unclear.  Our data show that OGT and OGA interact with Mi2β (a component of 
NuRD), GATA-1 and FOG-1. (Figure 11-13).  These data suggested that OGT and OGA are 
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part of the GATA-1/FOG-1/Mi2β repressor complex.  Mi2β or other components of the GATA-
1/FOG-1/Mi2β repressor complex may mediate the recruitment of OGT and OGA to the Aγ-
globin promoter.  Interestingly, we show that besides OGT, OGA also interacts with Mi2β, 
suggesting that O-GlcNAc cycling on Mi2β may be a potentially important mechanism for 
repressor complex assembly and transcriptional repression. Of note, OGT interacts with 
numerous transcription factors and mediates gene activation and silencing.  For example, OGT 
interacts with mSin3A recruiting OGT to promoters to repress transcription. Furthermore, 
inactivation of transcription factors and RNA polymerase II by O-GlcNAc modifications 
contribute to gene repression (27).  Drosophila polycomb group (PcG) gene (sxc) encodes for 
OGT, and null mutations in OGT lead to polycomb defects suggesting OGT is critical for PcG 
medicated gene silencing (28).   Potentially, OGT is mediating Mi2β repression of the Aγ-globin 
promoter. 
The transcription factor GATA-1 is essential for erythroid development. This DNA-
binding protein functions in either transcriptional activator or repressor protein complexes as the 
DNA-docking moiety, in either a FOG-1-dependent or independent fashion (36-39). A 
fundamental question remains as to what are the mechanisms that determine whether GATA-1 
functions in an activation complex or a repressor complex. In some instances, binding by partner 
protein TAL1 at a neighboring recognition site assures the recruitment of an activator complex 
(95), and to a limited degree the WGATAR binding site context plays a role (96).  However, 
these mechanisms do not explain the outcome for the majority of protein complex binding 
events.  The O-GlcNAcylation status of Mi2β during erythroid development may provide a 
mechanism by which different co-repressors or co-activators are recruited to interact with 
GATA-1. Moreover, GATA-1 itself may be a target of O-GlcNAcylation, influencing how it 
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interacts with co-activators or co-repressors.  In addition, FOG-1 also may be a target for O-
GlcNAcylation, and the differential post-translational modification of FOG-1 might determine 
the recruitment of different co-activators or co-repressors from those recruited by GATA-1 
alone. 
O-GlcNAcylation and phosphorylation can compete for specific Ser/Thr sites on a 
protein, or influence the PTM state of nearby Ser/Thr sites. For example, threonine 58 on c-Myc 
is reciprocally modified; phosphorylation promotes its degradation, but O-GlcNAc promotes its 
stability (97).  O-GlcNAcylation of C/EBPβ (CCAAT enhancer-binding protein β) influences 
adjacent phosphorylation sites.  O-GlcNAcylation of C/EBPβ Ser180 and Ser181 prevents the 
phosphorylation of Thr188, Ser184 and Thr179, which is required for C/EBPβ DNA binding 
activity (98).  Many phosphorylation sites have been mapped on Mi2β by mass spectrometry 
(99-104), and some of these sites could potentially be modified by O-GlcNAc. The reciprocal 
occupancy of GlcNAc or phosphate at these sites could fine tune Mi2β activity or interactions.  
Moreover, O-GlcNAcylation of Mi2β may also influence the phosphorylation state of specific 
sites on Mi2β and therefore its function in the formation of and/or within the GATA-1/FOG-
1/Mi2β repressor complex. In future studies, mapping Mi2β O-GlcNAc sites and exploring their 
biological function will be critical to understanding how O-GlcNAc cycling regulates the NuRD 
complex.  
In summary, we demonstrated that OGT and OGA associate with the Aγ-globin promoter 
(Figure 6 and 8); Inhibition of OGA by TMG leads to increased occupancy of OGT, OGA and 
Mi2β at the Aγ-globin promoter and decreased γ-globin transcription level (Figure 7); both OGT 
and OGA can interact with Mi2β, GATA-1 and FOG-1 (Figure 11-13); and Mi2β is O-
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GlcNAcylated (Figure 10). Our data indicate that Mi2β O-GlcNAcylation, OGT, and OGA 
facilitate assembly of the GATA-1/FOG-1/Mi2β (NuRD) repressor complex.  
Based on our findings, we propose that OGT/OGA contributes to the regulation of 
GATA-1/FOG-1/Mi2β mediated Aγ-globin gene repression. O-GlcNAc cycling on Mi2β is 
mediated by interactions with OGT and OGA (Figure 14a).  Potentially, O-GlcNAcylated Mi2β 
is recruited to -566 of Aγ-globin promoter with OGT and OGA by GATA-1 and FOG-1.  
Subsequently, Mi2β recruits other potential co-factors (Figure 14a and b) to form a stable 
repressor complex. At this point, the Aγ-globin transcription is repressed (Figure 14b). When Aγ-
globin transcription is activated, Mi2β interactions with OGT or other co-factors, is reduced, 
OGA removes O-GlcNAc from Mi2β, and the repressor complex is dissembled (Figure 14c). 
However, several questions still need to be addressed. How is GATA-1/FOG-1/Mi2β assembly 
affected when the OGT is altered?  Although Mi2β is modified by O-GlcNAc, are GATA-1, 
FOG-1 or other components of the NuRD complex modified by O-GlcNAc? Once the 
mechanistic role of O-GlcNAcylation in the assembly of the GATA-1/FOG-1/Mi2β repressor 
complex is understood, we may be able to target this complex to reverse γ-globin gene silencing 





Figure 6:OGT and OGA interact with the Aγ-globin promoter in CID-dependent β-YAC BMCs. 
a, WT CID-dependent β-YAC BMCs have a normal GATA motif that is bound by a GATA-
1·FOG-1·Mi2β repressor complex, mediating γ-globin repression; whereas −566 mutant CID-
dependent β-YAC BMCs have a T→G point mutation at nucleotide −566, which alleviates γ-
globin repression. b, γ-globin mRNA level in WT and −566 mutant β-YAC BMCs was analyzed 
by qPCR. Mouse HPRT was used as an internal control. c, Overall O-GlcNAc levels and OGA 
and OGT protein expression in total cell lysates from WT and −566 mutant CID-dependent β-
YAC BMCs were analyzed by immunoblotting. Actin was used as a loading control. d, OGT 
and OGA ChIP assays were performed on WT and −566 mutant β-YAC BMCs, respectively. 
ChIP DNA was analyzed by qPCR using a set of primers targeting the −566 GATA site of the 
Aγ-globin promoter. Normal rabbit (Rb) IgG served as a negative control. All experiments were 
performed with at least three biological replicates (* indicates p < 0.05, Student's t test). Error 




Figure 7:OGT, OGA, and Mi2β increase at the Aγ-globin gene promoter after TMG treatment in 
WT β-YAC BMCs. a, overall O-GlcNAc levels and OGA and OGT protein expression in total 
cell lysates from control and 4-day TMG-treated WT β-YAC BMCs cells were analyzed by 
immunoblotting. GAPDH was used as a loading control. b, γ-globin mRNA level in control and 
4-day TMG-treated WT β-YAC BMCs cells was analyzed by qPCR. Mouse HPRT was used as 
an internal control. OGT/OGA (c) and Mi2β (d) ChIP assays were performed on control and 4-
day TMG-treated WT β-YAC BMCs cells, respectively. ChIP DNA was analyzed by qPCR 
using a set of primers targeting the −566 GATA site of the Aγ-globin promoter. Normal rabbit 
IgG served as a negative control. All experiments were performed with four biological replicates 
(* indicates p < 0.05, Student's t test). Error bars represent S.E. WB, Western blotting. 
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Figure 8:OGT and OGA interact with the Aγ-globin promoter during fetal liver development in 
β-YAC transgenic mice. Mi2β (a), OGT (b), and OGA (c) ChIP assays were performed using 
postconception day E12 (γ-globin is expressed) and E18 (γ-globin is repressed) fetal liver single 
cell suspension prepared from β-YAC transgenic mouse conceptuses. ChIP DNA was analyzed 
by qPCR using a set of primers targeting the −566 GATA site of the Aγ-globin promoter. Normal 
rabbit IgG served as a negative control. All experiments were performed with at least three 










Figure 9:K562 γ-globin expression is increased after NaB induction. K562 cells were treated 
with NaB for 4 days. Cells were collected daily. a, γ-globin mRNA levels were measured before 
and after NaB induction by qPCR. b, overall O-GlcNAc levels and OGA and OGT protein 
expression from total cell lysates were analyzed by immunoblotting. Actin was used as a loading 
control. OGA (c) and OGT (d) mRNA levels were measured before and after NaB induction by 
qPCR. Human HPRT was used as an internal control in all qPCR analyses. All experiments were 
performed with at least three biological replicates (* indicates p < 0.05, Student's t test). Error 






Figure 10:Mi2β is modified by O-GlcNAc. a, O-GlcNAcylated protein was immunoprecipitated 
by an O-GlcNAc-specific antibody (CTD 110.6) in K562 cells before and after NaB induction 
(top panel) or H-H induction (bottom panel); the blot was probed with Mi2β antibody. b, Mi2β 
protein was immunoprecipitated from K562 cells before and after NaB induction (top panel) or 
H-H induction (bottom panel); the blot was probed with CTD 110.6. c and d, Mi2β protein was 
immunoprecipitated from K562 cells, and the blot was probed with CTD 110.6 (c) or CTD 110.6 
preincubated with 500 mM GlcNAc (d). e, Mi2β protein was immunoprecipitated from K562 
cells and treated with hexosaminidase CpNagJ at 37 °C for 3 h; the blot was probed with CTD 
110.6. The OGA inhibitor TMG was used to increase overall O-GlcNAc levels. Isotype 
immunoprecipitation (normal mouse IgM or rabbit IgG) and antibody-alone 
immunoprecipitation (1°) were used as negative controls. All experiments were performed with 




Figure 11:Mi2β interacts with OGT. a and b, OGT was immunoprecipitated with an OGT-
specific antibody (AL-34) in K562 cells before and after NaB induction (a) or hemin and HMBA 
induction (b), and the blot was probed with Mi2β antibody. c and d, Mi2β protein was 
immunoprecipitated from K562 cells before and after NaB induction (c) or hemin and HMBA 
induction (d), and the blot was probed with OGT antibody. The OGA inhibitor TMG was used to 
increase the overall O-GlcNAc levels. Isotype immunoprecipitation (normal rabbit or mouse 
IgG) and antibody-alone precipitation (1°) were used as negative controls. All experiments were 




Figure 12:Mi2β interacts with OGA. a and b, OGA was immunoprecipitated using an OGA-
specific antibody in K562 cells before and after NaB induction (a) or hemin and HMBA 
induction (b), and the blot was probed with Mi2β antibody. c and d, Mi2β protein was 
immunoprecipitated from K562 cells before and after NaB induction (c) or hemin and HMBA 
induction (d), and the blot was probed with OGA antibody. The OGA inhibitor TMG was used 
to increase overall O-GlcNAc levels. Isotype immunoprecipitation (normal chicken IgY or rabbit 
IgG) and antibody-alone immunoprecipitation (1°) were used as negative controls. All 








Figure 13:OGT and OGA interact with GATA-1 and FOG-1 in MEL birA cells. a, GATA-1 was 
immunoprecipitated using a GATA-1-specific antibody in MEL birA cells, and the blot was 
probed with OGA and OGT antibodies. b, FOG-1 was immunoprecipitated from MEL birA 
cells, and the blot was probed with OGT and Mi2β antibodies. c, OGA was immunoprecipitated 
from MEL birA cells, and the blot was probed with FOG-1 antibody. Isotype (IgY or IgG) 
immunoprecipitation and antibody-alone immunoprecipitation (without lysates) were used as 













Figure 14:Proposed mechanism of OGT/OGA regulation of GATA-1·FOG-1·Mi2β mediated 
Aγ-globin repression. a, O-GlcNAc (G) cycling on Mi2β is processed by OGT and OGA. 
Potentially, O-GlcNAcylated Mi2β is recruited to −566 of Aγ-globin promoter with OGT and 
OGA by GATA-1 and FOG-1. b, once O-GlcNAcylated Mi2β is recruited to the promoter, other 
potential cofactors (blue oval with “ ”) are recruited to the promoter as well to form a stable 
repressor complex, repressing Aγ-globin transcription. c, when Aγ-globin transcription is 
activated, Mi2β does not interact with OGT or other cofactors, and OGA removes O-GlcNAc 
from Mi2β, dissembling the repressor complex. 
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Chapter 4: O-GlcNAc Regulates GATA-1 Targeted Erythroid Gene Transcription 
Erythropoiesis is the process in which erythroid progenitors proliferate and differentiate 
into reticulocytes. Although erythropoiesis is regulated by numerous transcription factors, 
GATA-1, a transcription factor bearing a dual-zinc finger and WGATAR DNA binding motif, is 
the master regulator of erythroid differentiation (105-108). During erythroid differentiation, 
many GATA-1 target genes are activated or repressed (45,46,109,110). How GATA-1 mediates 
gene transcription activation versus repression is not well understood. For example, the co-
occupancy of GATA-1, Scl/TAL1, and other erythroid transcription factors, and the recruitments 
of transcription co-activator or repressor at specific gene loci, determine the GATA-1 target gene 
transcription status to some extend (41,42,45,111).  Epigenetic changes of histones and variation 
of WGATAR adjacent motif also play a role (40,43,45,46,112). These mechanisms provide a 
detailed view of DNA occupancy by GATA-1 with other transcription factors, and show that 
changes to chromatin structure during erythropoiesis influence GATA-1 function, however, these 
mechanisms do not explain the full breadth of GATA-1 regulation.  Potentially, post-
translational modifications (PTM) of transcription complexes during erythropoiesis could 
regulate GATA-1 function such as changing protein-protein interactions of transcription co-
activators or repressors or chromatin structure. We contend that O-GlcNAcylation is one of the 
PTMs contributing to GATA-1 regulation. 
O-linked β-N-acetylglucosamine (O-GlcNAc) is the modification of serine and threonine 
residues by β-D-N-acetylglucosamine. The sugar moiety is added and removed from serine and 
threonine residues by the O-GlcNAc processing enzymes, O-GlcNAc transferase (OGT) and O-
GlcNAcase (OGA), respectively (82). O-GlcNAc is critical for transcriptional regulation 
including both transcriptional activation and repression. For example, TET (ten-eleven 
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translocation) proteins and HCF-1 (host cell factor 1) co-localize with OGT at gene promoters 
associated with activating histone marks to promote target gene transcription (19,29,113,114). 
OGT also interacts with mSin3A and components of polycomb repressive complex (PRC) 1 and 
2 to mediate transcription repression by forming stable repressor complexes (27,115,116). OGA 
can localize to transcription start sites (TSS) overlapping with RNA polymerase II (117).  In our 
previous study, we also demonstrated that OGT and OGA interact with Mi2β, a component of   
GATA-1⋅FOG-1⋅Mi2β repressor complex, at the Aγ-globin promoter.  O-GlcNAcylation of Mi2β 
might modulate GATA-1⋅FOG-1⋅Mi2β repressor complex formation to regulate Aγ-globin 
transcription (118).   
In this study, we asked the question whether O-GlcNAc regulates GATA-1 targeted gene 
transcription during erythropoiesis. We utilized a well-established cell model of erythropoiesis, 
G1E-ER4 cells, a murine GATA-1 null erythroblast line that undergoes erythroid differentiation 
when GATA-1 activity is restored by the addition of β-estradiol (E2) (109,119). Interestingly, 
overall O-GlcNAc levels dramatically decreased upon GATA-1 activation with a slight increase 
in OGA and a decrease in OGT protein expression, and the interactions between GATA-1-ER 
and OGT/OGA were enhanced. We performed Next Generation RNA-Sequencing analysis on 
G1E-ER4 cells treated with E2 and/or Thiamet-G (TMG, an OGA inhibitor) and identified 
transcriptional alterations of 433 GATA-1 target genes when cells were treated with E2+TMG 
compared to E2 treatment only. We selected the GATA-1 target gene Laptm5 to investigate 
GATA-1 and OGT/OGA occupancy at the GATA-1 binding site during erythropoiesis. LAPTM5 
(lysosomal protein transmembrane 5) is specifically expressed on hematopoietic cells (120) and 
positively modulates inflammatory signaling pathways and cytokine secretion in macrophages 
(121).  Our ChIP data demonstrated that the occupancy of GATA-1 and OGT/OGA, and the 
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overall O-GlcNAc level at Laptm5 GATA binding site decreased when OGA is inhibited by 
TMG during erythropoiesis. Our data suggests that O-GlcNAc regulates specific GATA-1 target 
genes during erythropoiesis, OGA inhibition leads to an amplification of GATA-1 activation or 
repression, and suggest O-GlcNAcylation is a mechanism to control GATA-1 target gene 
transcription. 
4.1 Material and Methods 
Antibodies 
Primary antibodies and secondary antibodies for immunoblotting were used at 0.5 µg/ml 
and 1:10,000 dilution respectively. Antibodies for immunoprecipitation (IP) and chromatin 
immunoprecipitation (ChIP) assay were used at 2 µg per reaction. Antibodies for 
immunoblotting: Anti-OGT (AL-34) and OGA (345) were gracious gifts from the Laboratory of 
Gerald Hart in the Department of Biological Chemistry at the Johns Hopkins University School 
of Medicine.  Anti-O-linked N-acetylglucosamine antibody (RL2) (12440061), also used for IP 
and ChIP, and rabbit anti-goat IgG HRP (31402) were purchased from ThermoFisher Scientific. 
Anti-GAPDH antibody (ab9484) and anti-GATA2 antibody (ab109241) were purchased from 
Abcam. Anti-chicken IgY HRP (A9046) was purchased from Sigma. Goat anti-rabbit IgG HRP 
(170-6515) and goat anti-mouse IgG HRP (170-6516) were purchased from Bio-Rad. Goat anti-
rat IgG HRP (NA935V) was purchased from GE Healthcare. GATA-1 antibody (sc-265 X), also 
used for IP, and FOG antibody (sc-9361 X) were purchased from Santa Cruz Biotechnology. 
Antibodies for IP: Normal rabbit IgG (sc-2027), normal mouse IgG (sc-2025), and rat IgG (sc-
2026) were purchased form Santa Cruz Biotechnology.  Anti-OGT (DM-17) antibody (O6264) 
and anti-OGA antibody (SAB4200267) were purchased from Sigma. Antibodies for ChIP: 
Rabbit control IgG (ab46540) and anti-GATA1 antibody (ab11852) were purchased from 
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Abcam. ChIP grade mouse (G3A1) mAb IgG1 isotype control (5415) was purchased from Cell 
Signaling Technologies. OGT antibody (61355) was purchased from Active Motif.  Anti-OGA 
antibody (SAB4200267) was purchased from Sigma. 
Cell Culture 
G1E (GATA-1− Erythroid) and G1E-ER4 cells are kind gifts from Dr. Soumen Paul (The 
University of Kansas Medical Center). G1E is a GATA-1 null hematopoietic cell line derived 
from murine ES cells (119). G1E-ER4 cell line is a G1E designated subclone stably expressing 
fusion product of GATA-1 and human estrogen receptor ligand binding domain (GATA-1-ER) 
(109). G1E and G1E-ER4 cells were cultured in IMDM (12440061, ThermoFisher Scientific) 
supplemented with 15% heat-inactivated FBS (Gemini), 100 U/ml penicillin and 100 µg/ml 
streptomycin (P4333, Sigma), 120 nM 1-thioglycerol (M6145, Sigma), 2.5 U/ml recombinant 
mouse erythropoietin (rm EPO, 587606, Biolegend), and 50 ng/ml recombinant mouse stem cell 
factor (rm SCF, 78064.2, Stemcell Technology). Puromycin was added to the G1E-ER4 medium 
at 1 µg/ml to maintain selection pressure. Cells were incubated at 37°C, 5% CO2 in a 95% 
humidified incubator.  Cells were seeded at 4 x 104 cells/ml in T25 flasks with 10 ml culture 
medium overnight. Cells were then treated with 10 µM Thiamet-G (TMG, S.D. Specialty 
Chemicals) or/and 1 µM β-estradiol (E2, E2758, Sigma) (122). After 30 hrs, cells were harvested 
for subsequent analysis. 
Western Blot 
Cells were lysed on ice as described previously (118). Fifty µg of total cell lysates were 
used for electrophoresis and subjected to Western blot as previously described (118). All 
Western blot results were repeated in three independent experiments and representative images 
are shown.    
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Immuniprecipitation (IP)  
IP was performed as described previously (118). Two mg of cell lysates and 2 µg of 
antibody were used in each reaction. Forty µg of cell lysates were used as input. 
Benzidine Staining and May-Grünwald/Giemsa Stain 
Benzidine Staining was performed to access the hemoglobin content as described 
previously (109). Benzidine reagent was prepared by dissolving 60 mg of o-diansidine (D9143, 
Sigma) in 29.7 ml H2O and 0.5 ml glacial acetic acid. Prior to staining, one part of hydrogen 
peroxide (216763, Sigma) was added into 10 parts benzidine reagent.  
A hundred thousand cells were collected and resuspended with 100 µl of 1X PBS, 
followed by incubating with 10 µl of fresh benzidine preparation for 2 min. Cells were then 
loaded onto cytospin chambers (10-356, Fisher Scientific) and spun by a Shandon™ CytoSpin™ 
Centrifuge for 3 minutes at 700 rpm. Slides were air-dried, counterstained in May-Grünwald 
(MG1L, Sigma) for 5 seconds, and quick-washed twice in distilled water. Positive cells will be 
black, while negative will be light purple.  
May-Grünwald/Giemsa Stain was performed to access the morphology changes (109). 
Slides were prepared as described above, stained in May-Grünwald for 2 min, in fresh Giemsa 
(48900, Sigma, 1:20 dilution from stock) for 10 min, and quick-washed twice in distilled water. 
Cells staining images were visualized and taken under Nikon Eclipse 80i digital microscopy 
(Nikon Instruments INC, Melville, NY). 
Total RNA Isolation and RT-PCR 
Total RNA was isolated from 5 x 106 cells using TRI Reagent (T9424, Sigma) according 
to the manufacturer’s instructions.  For reverse transcription (RT), 0.5 µg of total RNA was 
reverse-transcribed to cDNA by iScript Reverse Transcription Supermix (170-8841, Bio-Rad) 
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following the manufacturer’s instructions.  Twenty µl of each completed reaction mix was 
incubated in a thermal cycler (Model 2720, Applied Biosystems) using the following protocol: 
priming 5 min at 25°C, RT 20 min at 46°C, RT inactivation 1 min at 95°C, and hold at 4°C. 
RNA-Sequencing 
RNA was extracted by Tri Reagent from three independent experiments. RNA 
sequencing library was prepared using Illumina TruSeq Stranded mRNA Library Preparation Kit 
Set A (RS-122-2101, Illumina) according to manufacturer’s instruction. Eight hundred ng of 
total RNA was used for the library preparation. Total RNA and sequencing library were analyzed 
by Agilent 2100 Bioanalyzer for quality control at KUMC Genome Sequencing Facility prior to 
sequencing. RNA library was sequenced at two lane flow cell Rapid Run mode using Illumina 
HiSeq 2500 Sequencing System composed of the HiSeq2500 sequencer, cBOT Clustering 
Station and the IlluminaCompute (iCompute) Server.  
RNA-Sequencing Data Analysis 
The FastQC (0.11.2) and RSEM (1.2.22) softwares were used to assess the quality of the 
RNA sequencing results, and align the reads to the mouse genome reference GRCm38/mm10 
and calculate the gene expression values, respectively. R (3.2.2) and EdgeR (3.14.0) softwares 
were used to normalize the expression values using the TMM-method (weighted trimmed mean 
of M-values), followed by differential expression analysis. First, we maximized the negative 
binomial conditional common likelihood to estimate a common dispersion value across all genes 
(estimateCommonDisp). Next, we estimated tagwise dispersion values by an empirical Bayes 
method based on weighted conditional maximum likelihood (estimateTagwiseDisp). Finally, we 
calculated the differentially gene expression by computing the genewise exact tests for 
differences in the means between two groups of negative-binomially distributed counts. To 
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reduce the burden of multiple testing in differential gene expression analyses, a filter was 
initially applied to reduce the number of genes. Genes were removed if they did not present a 
meaningful gene expression across all samples; only genes with cpm (counts per million) of >10 
in least two samples were considered in differential expression analyses. The Benjamini and 
Hochberg procedure was used to control the false discovery rate (FDR). The following R-
packages were utilized for calculations and visualizations: edgeR and Gplot.  
Chromatin Immuniprecipitation (ChIP) Assay 
The ChIP assay was performed using a previously described method (118,123) with 
slight modifications.  Briefly, chromatin was prepared and sheared as previously described (118). 
For each ChIP reaction, one hundred µl of sheared chromatin was diluted with 500 µl IP buffer 
(150 mM NaCl, 5 mM EDTA, 0.5% NP-40, 1% Triton X-100, 40 mM GlcNAc, and 50 mM 
Tris-HCl, pH 7.5), supplemented with protease inhibitor, and incubated with 2 µg of control IgG 
or specific antibody, respectively, at 4°C overnight.  Next day, 20 µl of PBS-washed Dynabeads 
Protein G (10004D, ThermoFisher Scientific) were added to the mixture, followed by rotation at 
4°C for 2 hrs.  Dynabeads were washed by 1 ml cold IP buffer 6 x for 5 min each wash, then 
mixed with 100 µl 10% Chelex 100 (1421253, Bio-rad) slurry; for input samples, 90 µl of 10% 
Chelex 100 was mixed with 10 µl of sheared chromatin. Briefly vortex ChIP samples and input 
samples and boil at 95 °C for 10 min, followed by treatment of 1 ul Rnase A (10 mg/ml) for 15 
min and 1 µl proteinase K (20 mg/ml) for 30 min at 55 °C. Samples were boiled again for 10 min 
to inactivate proteinase K and centrifuged at 12,000 g for 1 min at 4 °C. Seventy µl of 
supernatant was transferred to a new tube then 130 µl of DEPC-treated water (AM9906, 
ThermoFisher Scientific) was added to the beads and mixed well, followed by centrifugation. 
61 
 
One hundred and thirty µl of supernatant was collected and pooled with the previous supernatant 
for a total of 200 µl. DNA samples were stored at -20°C for subsequent qPCR analysis. 
Quantitative Polymerase Chain Reaction (qPCR) 
 qPCR was performed as described previously (118). Two µl of template for RT-qPCR or 
9.6 µl of template for ChIP-qPCR, 10 µl of SsoAdvanced Universal SYBR Green Supermix 
(172-5271, Bio-Rad), and 0.2 µl of each forward and reverse primers (100 µM) were mixed 
together in a total reaction volume of 20 µl.  The primer sequences for measuring target genes 
transcription levels are listed as following: Actb FWD TTTCCAGCCTTCCTTCTTGG, REV 
GGCATAGAG GTCTTTACGGATG; Hbb-b1 FWD GTGAGCTCCACTGTGACAAGCT, 
REV GGTGGC CCAGCACAATCACGATC (35); Fndc5 FWD 
CTCTGTCCCATTTCCTACCTTAC, REV GATGTTCACAGAGGGCTTCTT; Laptm5 FWD 
GATGGCAAGCTGTCCTTATCT, REV GTGTGATCACCAGACCCTAAAT; Mvb12a FWD 
CCCAAGATTTGAGGGCAAGA, REV CCACCACGAAGCCATAGTTATAC; Parp14 FWD 
CAGAGCATGGCCTTGAGATAA, REV CCAGTGCCAGAAAGGAGAAA. The primer 
sequences for measuring ChIP DNA quantity are listed as following: +8 kb Laptm5 TSS 
(GATA-1 binding site) FWD GGTGTTGTGGTGGCATATAGA, REV 
CCGCTTCCTGTCACAGTTTA; +58 kb Laptm5 TSS FWD CCCAGTGCTTTGTCTGTTACT, 
REV GCTCTGAAGTGATTCGAGGAAA. The reactions were run in a CFX96 Touch Real-
Time PCR Detection System (185-5195, Bio-Rad) as described previously (118). 
qPCR Data Analysis 
Quantification cycle (Cq) values were calculated by CFX Manager™ software.  For 
cDNA qPCR data, the dynamic range of RT and amplification efficiency were evaluated before 
applying the ∆∆Cq method to calculate relative gene expression change.  The transcription level 
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of the target gene was normalized to the internal control as fold change. For ChIP DNA qPCR 
data, the Cq value was normalized as percent of input. Data generated in at least three 
independent experiments are presented as mean ± standard error; the two-tailed Student t-test 
statistic was applied with P < 0.05 considered to be a significant difference. 
Gene Set Enrichment Analysis (GSEA) 
GSEA was performed according to the “GSEA USER GUIDE” (124,125). For gene 
ontology (GO) analysis, biological processes gene sets from Molecular Signature Database 
(MsigDB) were used. Pathways with NOM (Nominal) p-value < 5% and FDR q-value < 25% 
were included into the analysis. 
4.2 Results 
O-GlcNAc Levels Decrease upon GATA-1 Restoration 
In order to determine the role of O-GlcNAc during erythropoiesis, we first used a well-
established erythropoiesis model system.  G1E (GATA-1− erythroid) is a GATA-1 null 
hematopoietic cell line derived from murine ES cells (119). The G1E-ER4 cell line is a G1E 
designated subclone stably expressing GATA-1-ER, a fusion product of GATA-1 and human 
estrogen receptor ligand binding domain (109). Upon restoring GATA-1 activity by adding β-
estradiol (E2) for 30 hrs, G1E-ER4 cells undergo red blood cell differentiation and recapitulate a 
stage from late BFU-E (burst forming unit-erythroid) to basophilic erythroblasts (109,122), 
characterized by decreased cell size, hemoglobin accumulation, nuclear condensation, and cell 
membrane organization. After GATA-1 restoration by E2 treatment, GATA-1-ER expression 
was increased as reported previously (Figure 15a) (126,127); GATA-2 transcription is repressed 
by GATA-1, resulting in the decrease of GATA-2 protein level (43) (Figure 15a); GATA-1 
target gene FOG-1 protein level (Figure 15a) and β-major globin gene transcription level 
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(Figure 15e) were increased. At the same time, the morphologic maturation (Figure 15c) and 
hemoglobin induction (Figure 15d) were observed in G1E-ER4 cells treated with E2. In order to 
determine how changes in O-GlcNAcylation could affect GATA-1 induced differentiation, we 
treated cells with both E2 and TMG, an OGA inhibitor. TMG+E2 did not change the cell 
morphology (Figure 15c), hemoglobin induction (Figure 15d), and β-major globin gene 
transcription level (Figure 15e) compared to E2 treatment only. Interestingly, the O-GlcNAc 
levels were dramatically decreased after E2 treatment, with an increase of OGA and a decrease 
of OGT protein expression. When G1E-ER4 cells were treated with E2 following a time course, 
we found that the O-GlcNAc levels at 30 hrs were the lowest compared to other time points 
(Figure 15b). However, the O-GlcNAc levels, and OGT/OGA expression in G1E cells did not 
change at 30 hrs compared to 0 hr (Figure 15a and b). These data indicate that O-GlcNAc levels 
decrease upon GATA-1 restoration and erythroid differentiation.  
GATA-1 Interacts with OGT and OGA in G1E-ER4 Cells 
Our previous study demonstrated that OGT and OGA interact with GATA-1⋅FOG-
1⋅Mi2β repressor complex, and Mi2β-OGT/OGA interaction pattern changes when γ-globin 
transcription level is altered (118). To address how OGT/OGA interact with GATA-1 during 
G1E-ER4 differentiation, we performed immunoprecipitation (IP) using antibodies against O-
GlcNAc (RL2), OGT, OGA, and GATA-1 from G1E-ER4 cell lysates treated with TMG or/and 
E2 (Figure 16). We found that little GATA-1-ER could be pulled down by O-GlcNAc, OGT, or 
OGA antibody before E2 treatment, however, O-GlcNAc, OGT, and OGA antibody all can 
robustly IP GATA-1-ER after E2 treatment (Figure 16a-c); these antibodies can also pull down 
FOG-1 before and after E2 treatment, and E2 treatment increased the amount of 
immunoprecipitated FOG-1 with a molecular weight shift suggesting an increase in FOG-1 
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phosphorylation (128,129) (Figure 16a-c). GATA-1 antibody can IP OGT/OGA before and after 
E2 treatment (Figure 16d). We also performed co-IP to test if GATA-1 or FOG-1 could be 
modified by O-GlcNAc, however, we could not detect the O-GlcNAcylation of GATA-1 or 
FOG-1 by Western blot (data not shown). These data indicate that the interaction between 
GATA-1 and OGT/OGA, and the O-GlcNAcylation of GATA-1 interacting proteins increase 
during G1E-ER4 cell differentiation.  
Inhibition of OGA Changes Erythroid Gene Transcription Network 
Since O-GlcNAc plays an important role in transcription regulation and OGT/OGA 
interact with GATA-1, we tested if the erythroid gene transcription network was altered by 
disruption of O-GlcNAcylation during G1E-ER4 differentiation. We performed Next Generation 
RNA-seq analysis on G1E-ER4 cells without any treatment, and with TMG and/or E2 treatment 
for 30 hrs. 8,271 transcripts were included into the RNA-seq analysis from the different 
treatments, and the shared gene numbers of down-regulated (Figure 17a) and up-regulated genes 
(Figure 17b) are showed in Venn diagram. Our RNA-seq data suggest that inhibition of OGA by 
TMG changes transcription levels of numerous genes during erythropoiesis. In order to 
characterize the biological processes altered by inhibition of OGA, GSEA (Gene Set Enrichment 
Analysis) analysis of the 8,271 transcripts was performed (124,125). Top 10 up- (top panel) and 
down-regulated (bottom panel) biological processes (Figure 17c) and examples of enrichment 
plots (Figure 17d) were listed respectively, comparing TMG+E2 with E2 treatment only.  
Interestingly, biological processes of myeloid leukocyte activation and inflammatory response 
were up-regulated, which indicated that inhibition of OGA during erythropoiesis might activate 
some leukocyte gene programs usually repressed during erythroid differentiation. These results 
indicate that many biological processes were changed when OGA was inhibited during 
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erythropoiesis, and these changes might enable erythroid cells to gain some leukocyte 
characteristics during differentiation. 
We compared the transcription profile of G1E-ER4 cells treated with E2+TMG with E2 
only (Figure 18a). 1,173 transcripts were differentially expressed in E2+TMG compared to E2 
treatment only, and 530 genes were up-regulated while 643 down-regulated (Figure 18b-c). 
These data demonstrated that the G1E-ER4 transcriptome was altered with inhibition of OGA 
during differentiation. 
O-GlcNAc Regulates GATA-1 Target Gene Transcription during Erythropoiesis 
GATA-1 is a master transcription factor during erythropoiesis and is important for 
erythroid maturation (106,130). Our data demonstrated that inhibition of OGA can alter gene 
transcription profiles during erythropoiesis; therefore, O-GlcNAc could regulate GATA-1 target 
gene transcription. We used an online database Harmonizome (131) to search for GATA-1 target 
genes in G1E-ER4 after E2 treatment. Totally 4,072 GATA-1 target genes were found from 
ENCODE transcription factor binding site profiles (45,132), and 433 of them are differentially 
expressed in TMG+E2 compared with E2 only (Figure 18d). Of these 433 genes, 243 genes 
were up-regulated and 190 genes down-regulated (Figure 18d). Similar GSEA analysis was 
performed on these 433 genes. Interestingly, immune response and defense response biological 
processes, which are characteristics of leukocytes, were also up-regulated in TMG+E2 treated 
cells compared to E2 only (data not shown). Our data demonstrated that a subset of GATA-1 
target genes is regulated by O-GlcNAc during erythropoiesis.  
In order to assess the quality of our RNA-Seq data analysis and confirm the differential 
expression of candidate genes, we selected 4 genes to perform qPCR analysis. Laptm5, Fndc5, 
Parp14, and Mvb12a are all GATA-1 target genes, which also have a robust transcriptional 
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change with TMG+E2 treatment compared to E2 only. Total RNA was extracted from cells with 
control, TMG or/and E2 treatment, and qPCR analysis was performed. After E2 treatment for 30 
hrs, Laptm5, Fndc5, and Parp14 transcription level was increased compared to control (Figure 
19a-c), while Mvb12a decreased (Figure 19d). When cells were treated with TMG+E2, Laptm5, 
Fndc5, and Parp14 transcription level was increased compared to E2 only (Figure 19a-c), while 
Mvb12a decreased (Figure 19d). These results were consistent with the fold change from RNA-
Seq data.  
Inhibition of OGA Decreases the Occupancy of GATA-1, OGT/OGA, and O-GlcNAc level 
at the Laptm5 GATA Binding Site 
Since inhibition of OGA by TMG altered a subset of GATA-1 target genes during 
erythropoiesis, we explored the association of O-GlcNAc, OGT, and OGA at GATA-1 target 
gene Laptm5. LAPTM5 is specifically expressed in hematopoietic cells (120) and positively 
modulates inflammatory signaling pathways and cytokine secretion in macrophages (121). The 
Laptm5 gene has a GATA binding site located at the first intron, approximately 8 kb downstream 
of TSS (45). We performed ChIP assays using antibody against GATA-1, OGT, OGA, and O-
GlcNAc to assess the occupancy of GATA-1, OGT, OGA, and overall O-GlcNAc level at the 
GATA binding site during erythropoiesis.  
In control G1E-ER4 cells, we saw the occupancy of OGT/OGA near Laptm5 GATA 
binding site, which was also modified by O-GlcNAc (Figure 20b-d), suggesting that O-
GlcNAcylation near Laptm5 GATA binding site might be important to maintain the Laptm5 
repression state. Upon GATA-1 restoration by E2, GATA-1 occupancy dramatically increased at 
the GATA binding site compared to control, however, its occupancy decreased at the same site 
when cells were treated with E2+TMG (Figure 20a, left panel); OGT occupancy did not change 
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and OGA occupancy increased at the GATA binding site after E2 treatment compared to control 
(Figure 20b and c, left panel), which might contribute to the decrease of the overall O-GlcNAc 
levels at the GATA binding site (Figure 20d, left panel). Interestingly, the occupancy of OGT, 
OGA, and overall O-GlcNAc level at GATA binding site decreased after TMG+E2 compared to 
E2 (Figure 20b-d, left panel), and the similar pattern was observed when comparing TMG 
treatment only with control (Figure 20b-d, left panel). In order to show that these changes were 
specific to the GATA binding site, we used a DNA region 50 kb downstream of the GATA 
binding site as a negative control. As expected, we did not find any changes comparing 
TMG+E2 with E2 only (Figure 20a-d, right panel). Our data demonstrated that the occupancy 
of GATA-1 and OGA, and overall O-GlcNAc level at Laptm5 GATA binding site was changed 
upon GATA-1 restoration, and these changes could be disrupted by inhibition of OGA.  
4.3 Discussion 
We utilized a well-established erythropoiesis model (G1E-ER4 cells) to investigate the 
role of O-GlcNAc during GATA-1 mediated erythroid differentiation. After restoration of 
GATA-1 activity for 30 hrs, interestingly, overall O-GlcNAc levels dramatically decreased, with 
an increase of OGA and a decrease of OGT protein levels (Figure 15a and b). Restoration of 
GATA-1 also promoted the interaction of GATA-1-ER with OGT and OGA (Figure 16b-c). 
Next, we performed RNA-Seq analysis of G1E-ER4 cells treated with E2 and TMG. 1,173 genes 
changed transcription level compared to cells treated with E2 only (Figure 18b), including 433 
GATA-1 target genes (Figure 18d). The transcription level changes were further confirmed by 
qPCR (Figure 19). Our ChIP assay demonstrated that the occupancy of GATA-1 and OGA, and 
overall O-GlcNAc level at Laptm5 GATA binding site were changed upon GATA-1 activation, 
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and these changes were diminished by inhibition of OGA (Figure 20). Our data suggests that O-
GlcNAc plays a role in regulating a subset of GATA-1 controlled erythroid genes.   
O-GlcNAc regulates cell differentiation and development (133,134). The overall O-
GlcNAc level decreases during embryonic stem cell (ESC) neural differentiation (135), 
epidermal keratinocytes (136), cardiomyocytes (137), myoblasts (138), and leukemia K562 cell 
differentiation (118); while overall O-GlcNAc levels increased during differentiation of mouse 
chondrocyte (139) and osteoblast  cells (140). Here, we observed a dramatic decrease of overall 
O-GlcNAc levels in G1E-ER4 cells after E2 induction for 30 hrs, and even more reduction at 48 
hrs (data not shown), with decreased OGT and increased OGA protein level (Figure 15a and 
b); however, the overall O-GlcNAc and OGT/OGA protein levels did not change in G1E cells at 
30 hrs compared to control (Figure 15a and b). We do not know whether the decrease of overall 
O-GlcNAc levels is a characteristic of all hematopoietic linage differentiation or only specific for 
erythroid differentiation and how OGT and OGA are regulated to maintain the O-GlcNAc levels 
during erythropoiesis. Nor do we know whether this decrease is a driving force for 
differentiation or a result of differentiation.  However, our data does recapitulate the data from 
differentiated cells lines showing a decrease in overall O-GlcNAcylation and suggesting that in 
most cells, differentiation requires a reduction in O-GlcNAc levels. 
Numerous studies show that OGT, OGA, and O-GlcNAc are critical for transcription 
regulation (19,25,26,141). O-GlcNAc can modulate transcription activator or repressor 
complexes by the interactions of OGT/OGA with the components of protein complexes (27,118). 
O-GlcNAc is part of the histone code (18,19) and modulates other epigenetic changes on DNA 
or histones, such as DNA methylation (29,114), and histone acetylation (27) or methylation 
(114,115) affecting chromatin structure and leading to transcription activation or repression. 
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OGT and OGA regulates preinitiation complex (PIC) formation and RNA Pol II activity 
(24,117,142). Since GATA-1 expression increases with E2 treatment only, more GATA-1-ER 
was immunoprecipitated after E2 treatment by an O-GlcNAc, OGT, and OGA antibody 
respectively compared to control (Figure 16a-c). We did not find GATA-1 itself could be 
modified with O-GlcNAc by IP (data not shown); however, GATA-1 interacting proteins are 
likely modified by O-GlcNAc since upon differentiation, the O-GlcNAc antibody can pull down 
GATA-1-ER (Figure 16a) despite the decrease of overall O-GlcNAc levels in the total cell 
lysates compared to control (Figure 15a). The changes of OGT/OGA protein level, their 
interaction with GATA-1-ER, and O-GlcNAc levels of GATA-1-ER interacting proteins during 
erythropoiesis, could change protein-protein interaction of GATA-1 mediated activator or 
repressor complexes, chromatin structure, and RNA Pol II activity of GATA-1 target genes. All 
these events during erythropoiesis could contribute to GATA-1 mediated gene activation or 
repression. 
In order to explore the role of O-GlcNAc during erythropoiesis, we pharmacologically 
inhibited OGA by TMG in G1E-ER4 with or without E2 treatment, and then performed RNA-
seq analysis. Inhibition of OGA by TMG during G1E-ER4 differentiation leads to many 
erythroid genes being more activated or repressed compared to E2 treatment only. When we ran 
GSEA using our data set, interestingly, we found that biological process of myeloid leukocyte 
activation is significantly enriched, and tRNA metabolic process attenuated in TMG+E2 
compared to E2 treatment only (Figure 17c). These data suggest inhibition of OGA by TMG 
changes gene transcription and protein synthesis profiles during erythropoiesis, and these 
changes might reprogram the cell and result in myeloid leukocyte-like cell morphology or 
behavior. However, it would be interesting to explore if O-GlcNAc plays a role in determining 
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hematopoietic cell fate at an earlier stage, for example, inhibition of OGA by TMG in 
hematopoietic stem cell stage before lineage commitment occurs and then determine if changes 
in O-GlcNAc skew hematopoietic stem cells differentiation toward a particular lineage.  
We selected 1,173 differentially expressed genes (TMG+E2 compared to E2 only) and 
determined which of those genes were GATA-1 targeted using an online database (131). We 
found 433 differentially expressed genes under control of GATA-1 with 243 genes up-regulated 
and 190 down-regulated (Figure 18d). Interestingly, 84% of activated GATA-1 target genes 
became more activated in the presence of TMG; while 79% repressed GATA-1 target genes 
became more repressed in the presence of TMG, indicating that inhibition of OGA amplifies 
GATA-1 mediated transcription. Recently, we showed that in WT β-YAC bone marrow cells, 
transcription of Aγ-globin was repressed by GATA-1⋅FOG-1⋅Mi2β repressor complex, and TMG 
treatment in these cells led to even more repression of Aγ-globin transcription (118). These data 
point to a compelling phenomenon in which O-GlcNAc cycling at GATA-1 binding sites 
controls the strength of the transcriptional response. If O-GlcNAc cycling randomly promotes 
the formation of GATA-1 mediated activator or repressor complexes, we would anticipate TMG 
would amplify activation or repression of GATA-1 target genes randomly regardless of whether 
GATA-1 activates or represses these genes during erythropoiesis.  Instead, we found that the 
transcription levels of most GATA-1 target genes were amplified when O-GlcNAc cycling was 
disrupted. These data argue that O-GlcNAc cycling does not dictate the activation or repression 
of GATA-1 target genes but finely tunes the actions of GATA-1 mediated activator or repressor 
complexes at GATA binding sites.  Importantly, this might be a general phenomenon of O-
GlcNAc cycling at gene promoters or other protein complexes and warrants further investigation. 
One of the GATA-1 target genes is Laptm5, which is specifically expressed in 
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hematopoietic cells (120).  LAPTM5 positively modulates inflammatory signaling pathways and 
cytokine secretion in macrophages (121). The transcription of Laptm5 was activated upon 
GATA-1 restoration and was enhanced in the presence of TMG (Figure 19a).  Strikingly, the 
occupancy of GATA-1, OGT/OGA, and O-GlcNAc level at Laptm5 GATA binding site 
decreased after inhibition of OGA upon GATA-1 restoration (Figure 20). These changes could 
lead to the recruitment of other transcription co-activators or open chromatin structure at Laptm5 
GATA binding site resulting in an increase of Laptm5 transcription compared to E2 treatment 
only. Even though GATA-1 occupancy at Laptm5 GATA binding site was decreased in 
TMG+E2 treatment (Figure 20a), TMG amplified the increase of Laptm5 transcription 
compared to E2 treatment only (Figure 19a). This suggests that TMG treatment could stabilize 
the interaction of GATA-1 with other transcription factors at the GATA binding site reducing the 
recruitment or turnover of these transcription factors. Hence a reduced occupancy of GATA-1 at 
the GATA binding site, but GATA-1 is either more stable or more active in promoting 
transcription.  However, it is unknown what are these transcription factors at the Laptm5 GATA 
binding site.  
Based on our data, we propose that OGT and OGA are important in regulating GATA-1 
target gene Laptm5 transcription during erythropoiesis. In normal G1E-ER4 cells, Laptm5 
transcription is repressed by an O-GlcNAcylated repressor complex, which interacts with 
OGT/OGA near the GATA binding site (Figure 21a). Upon GATA-1 restoration by E2, GATA-
1 is recruited to GATA site located in the first intron of Laptm5, followed by the recruitment of a 
transcription activator complex activating Laptm5 transcription (Figure 21a). OGT interacts and 
modifies the component(s) of this transcription activator complex promoting the recruitment of 
other transcription co-activators. OGA then removes the O-GlcNAc to form a stable activator 
72 
 
complex. This process is similar to the preinitiation complex formation regulated by OGT and 
OGA (142). When OGA is inhibited by TMG during erythropoiesis, the O-GlcNAc cycling on 
the activator complex is disrupted, leading to the decreased occupancy of OGT, OGA, and 
GATA-1 at the GATA binding site. The components of the activator complex might also change 
(Figure 21b). However, this new activator complex could be more stable and active due to the 
changes in protein-protein interactions within the complex or chromatin structure resulting in 
even more active transcription of Laptm5 (Figure 21c).  These data suggest that inhibition of 
OGA by TMG could affect a subset of GATA-1 target gene transcription by enhancing the gene 
activation or repression. 
In summary, we induced G1E-ER4 cells with E2 to investigate the role of O-GlcNAc 
during erythropoiesis. Our data suggests that O-GlcNAc plays an important role in regulating 
GATA-1 target genes transcription during erythropoiesis. Finally, we demonstrate that reduced 
O-GlcNAc cycling enhanced GATA-1 mediated gene activation or repression providing a novel 
mechanism as to how O-GlcNAcylation can promote GATA-1 targeted gene transcription 













Figure 15: O-GlcNAc levels decrease upon GATA-1 restoration. G1E and G1E-ER4 cells were 
treated with TMG (OGA inhibitor) or/and E2 for 30 hrs. Cells were harvested at (a) 30 hrs or (b) 
following a time course, and total cell lysates were subjected to immunoblotting. G1E-ER4 cells 
were subjected to (c) May-Grunwald Giemsa (GMM) staining for cell morphology and (d) 
benzidine staining (BZ) for hemoglobin content. Red arrow shows hemoglobin positive cells. e. 
Transcription level of β-major globin gene (Hbb-b1) was measured by qPCR. and β-actin (Actb) 




Figure 16:GATA-1 interacts with OGT and OGA in G1E-ER4 cells. G1E-ER4 cells were 
treated with TMG (T) or/and E2 for 30 hrs. Cells were harvested and subjected to 
immunoprecipitation (IP). O-GlcNAcylated protein, OGT, OGA, and GATA-1-ER were 
immunoprecipitated with a specific (a) O-GlcNAc antibody (RL2), (b) OGT, (c) OGA, and (d) 
GATA-1 antibody, respectively.  Blots were probed with RL2, GATA-1, FOG-1, OGT, OGA, 
and GAPDH respectively. Isotype (normal rabbit or mouse IgG) IP and antibody alone 






Figure 17: Inhibition of OGA changes gene transcription network during erythropoiesis. Venn 
diagram of (a) down- and (b) up-regulated transcripts in TMG, E2, and TMG+E2 treatment 
compared to control, respectively. Transcripts with p value<0.05 and FDR (False Discover Rate) 
<0.05 were included in the analysis. c. Top 10 up- (top) and down-regulated (bottom) biological 
processes analyzed by GSEA are ranked by NES (Normalized Enrichment Score). d. Enrichment 
plot of an up-regulated biological process myeloid leukocyte activation (left) and down-regulated 
biological process tRNA metabolic process (right). NOM (Nominal) p-value < 5% and FDR q-




Figure 18: O-GlcNAc regulates GATA-1 target Gene transcription during erythropoiesis. a. The 
Volcano Plot of differentially expressed genes in E2+TMG compared to E2 treatment only. The 
negative log of P value is plotted on the Y-axis, and the log of the fold change (FC) is plotted on 
the X-axis. b, 1,173 genes were differentially expressed in E2+TMG compared to E2 treatment 
only. Pie chart shows the distribution of up- (45%) and down-regulated (55%) genes 
differentially expressed. Transcripts with p value < 0.05 and FDR < 0.05 were included in the 
analysis.  c, The heat map of top 20 differentially expressed genes. d, Venn diagram of 
differential expression of 1,173 genes (TMG+E2 versus E2) and 4,072 GATA-1 targeted genes 
from database. Of 433 differentially expressed GATA-1 target genes, 243 genes were up-




Figure 19:Validation of O-GlcNAc regulated GATA-1 target gene by qPCR. Transcription level 
of GATA-1 target genes (a) Laptm5, (b) Fndc5,  (c) Parp14, and (d) Mvb12a was analyzed by 
qPCR after cells were treated with TMG or/and E2. The experiments were repeated 4 times. β-










Figure 20: Inhibition of OGA decreases the occupancy of GATA-1, OGT/OGA, and O-GlcNAc 
level at Laptm5 GATA Binding Site. (a) GATA-1, (b) OGT, (c) OGA, and (d) O-GlcNAc (RL2) 
ChIP assays were performed using G1E-ER4 cells treated with TMG or/and E2. ChIP DNA was 
analyzed by qPCR using a set of primer targeting the Laptm5 GATA binding site (+ 8 kb TSS) 
and +58 kb TSS respectively. Normal rabbit IgG served as a negative control. All experiments 




Figure 21: Proposed mechanism of OGT/OGA mediated repression and activation of GATA-1 
target gene Laptm5 during erythropoiesis. In normal G1E-ER4 cells, Laptm5 transcription is 
repressed by an O-GlcNAcylated repressor complex (red oval), which localized at the first intron 
and interacts with OGT/OGA near the GATA binding site. Upon GATA-1 restoration by E2, 
GATA-1 is recruited to GATA site located in the first intron of Laptm5, followed by the 
recruitment of an O-GlcNAcylated transcription activator complex (orange oval), then Laptm5 
transcription is activated (a). When OGA is inhibited by TMG during erythropoiesis, the O-
GlcNAc cycling on the activator complex is disrupted, leading to the decreased occupancy of 
OGT, OGA, and GATA-1 at the GATA binding site (b). The remaining activator complex (pink 
oval) could be more stable and active due to the changes of protein-protein interactions within 
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